

**RICHARD DE LA GARZA, II, PH.D.**

**CURRICULUM VITAE**

[WWW.RESEARCHERID.COM/RID/B-2489-2014](http://WWW.RESEARCHERID.COM/RID/B-2489-2014)  
[WWW.SCOPUS.COM/AUTHID/DETAIL.URL?AUTHORID=7003906211](http://WWW.SCOPUS.COM/AUTHID/DETAIL.URL?AUTHORID=7003906211)

**Contact Information:**

Business: Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, 1977 Butler Blvd., Ste. E4.163, Houston, TX 77030, 713-791-1414 x26020 (work phone).

Home: 3310 Yupon Street, Houston, TX 77006, 832-370-7875 (cell phone)

**Education:**

1981-1985 B.S., Biology, Texas A&M University-Commerce, Commerce, TX

1986-1989 M.S., Biology, University of North Texas, Denton, TX

1991-1996 Ph.D., Neuroscience, University of Texas Medical Branch, Galveston, TX,

1996-1999 Post-Doctoral Fellow, Harvard Medical School

1999-2000 Post-Doctoral Fellow, Yale University School of Medicine

**Current Faculty Positions:**

2013-present Professor *with tenure*, Baylor College of Medicine (BCM), Menninger Department of Psychiatry & Behavioral Sciences, Department of Neuroscience, and Department of Pharmacology

Professor, Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Research Services Line

Adjunct Professor, University of Texas Medical Branch, Department of Pharmacology

Adjunct Professor, University of Houston, Department of Psychology

2014-present Professor and Director of Research, University of Texas M. D. Anderson Cancer Center (MDACC), Department of Psychiatry, and Associate Professor Department of Behavioral Science

**Previous Faculty Positions:**

2008-2014 Associate Professor and Director of Research, University of Texas M. D. Anderson Cancer Center (MDACC), Department of Psychiatry, and Associate Professor Department of Behavioral Science

2008-2013 Associate Professor *with tenure*, Baylor College of Medicine (BCM), Menninger Department of Psychiatry & Behavioral Sciences, Department of Neuroscience, and Department of Pharmacology

Associate Professor, Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Research Services Line

Adjunct Associate Professor, University of Texas Medical Branch, Department of Pharmacology

2011-2013 Adjunct Associate Professor, University of Houston, Department of Psychology

2007-2008 Visiting Associate Professor in Residence, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Department of Psychiatry and Biobehavioral Sciences.

2004-2007 Associate Research Neuroscientist and Lecturer, David Geffen School of Medicine at UCLA, Department

of Psychiatry and Biobehavioral Sciences

2000-2004 Assistant Professor, Albert Einstein College of Medicine, Department of Psychiatry and Behavioral Sciences and Department of Neuroscience

1999-2000 Associate Research Scientist, Yale University School of Medicine, Department of Psychiatry

### **Research Experience:**

- 2008-*present* Medications development and testing for cocaine, methamphetamine and tobacco use disorders. Use of virtual reality for cue-induced craving and use of functional magnetic resonance imaging and other neuroimaging modalities to identify neural substrates of reward processing, cue reactivity, and treatment response.
- 2004-2008 Studies on the neurobiology of substance abuse in cocaine- and methamphetamine-dependent research participants. Focus on phase I clinical trials of candidate medications, gene association studies. At UCLA, I developed the first intravenous methamphetamine self-administration assay for humans.
- 2000-2004 Studies on the neurobiology of addiction using rodent models. Focus on nicotine, MDMA and cocaine self-administration, molecular biology (gene expression analyses) and neurochemistry (HPLC).
- 1999-2000 Studies on the neurobiology of addiction using rodent and non-human primate models. Focus on cocaine-induced behavioral changes and neurochemistry (*in vivo* microdialysis and *in vitro* tissue HPLC).
- 1996-1999 Studies on the neurobiology of addiction using non-human primate models. Focus on cocaine-induced behavioral changes, molecular biology (including cloning of DAT sequences), and neurochemistry (autoradiography). At Harvard, I developed the first autoradiographic map of DA D<sub>4</sub> receptors in non-human primates.
- 1993-1996 Studies on the neurobiology of addiction using rodent models. Focus on cocaine-induced behavioral changes including drug discrimination and locomotor sensitization, with specific emphasis on serotonin systems.
- 1986-1989 Studies on neuronal morphology of fetal mouse spinal monolayer cultures. Utilization of intracellular injections and anterograde transport for labeling of neurons followed by light microscopy neuron reconstruction via camera lucida drawings and morphometric analyses.

### **Leadership Experience:**

- 2014-*present* Member, External Advisory Board, Center for Drug & Social Policy Research, University of Houston.
- 2014-*present* Member, Advisory Board, Center for the Neurobiology of Addiction Treatment, Wake Forest University School of Medicine.
- 2014-*present* Member, External Advisory Board, Diversity-promoting Institutions Drug Abuse Research Program, Meharry Medical College
- 2014-*present* Co-Chair, Membership Committee, National Hispanic Science Network on Drug Abuse
- 2014-2015 Co-Chair, Conference Planning Committee, National Hispanic Science Network on Drug Abuse
- 2013-*present* National Steering Committee, National Hispanic Science Network on Drug Abuse
- 2008-*present* Director of Research, MDACC, Department of Psychiatry
- 2008-*present* Co-Director, NIDA R25 Clinical Research Education for Drug Abuse Professionals Training Grant
- 2011-2014 Executive Committee, College on the Problems of Drug Dependence
- 2012- 2013 Chair, Executive Officer Search Committee, College on the Problems of Drug Dependence
- 2012- 2013 President, College on the Problems of Drug Dependence
- 2011-2014 Member, Advisory Board, MDACC Cancer Prevention Research Training Program in Statistical Genetics
- 2011-2013 BCM Presidents' Research Working Group, Strategic Planning, Experimental Therapeutics Subgroup
- 2011-2013 BCM Presidents' Research Working Group, Strategic Planning, Technology Transfer Subgroup

2010-2014 MEDVAMC, Steering Committee, Traumatic Brain Injury Center of Excellence,  
 2011-2012 Chair, Nominations Committee, College on the Problems of Drug Dependence  
 2008-2014 Elected Member, Board of Directors, College on the Problems of Drug Dependence  
 2008 Co-Director, NIDA T32 Training Grant UCLA  
 2006-2009 Chair, Publications Committee, College on the Problems of Drug Dependence  
 2004-2008 Co-Founder, UCLA Brain Research Institute, Stress in Stimulant Abuse and Addiction Affinity Group

#### Honors or Awards:

1993 Society for Neuroscience, travel fellowship for annual meeting  
 1993, 1994 National Hispanic Scholarship Fund, Scholar Award  
 1994 University of Texas Medical Branch (UTMB) Sigma Xi Award, travel fellowship for Society for Neuroscience annual meeting  
 1994, 1995 UTMB-Jason E. Pearlman Award, Behavioral Neuroscience Research Award  
 1995 National Student Research Forum, Bohdan R. Nechay Pharmacology Research Poster Award  
 1995 American College of Neuropsychopharmacology (ACNP), travel fellowship for ACNP annual meeting  
 1995 ACNP-Upjohn Summer Research Fellowship to perform research at the University of Pittsburgh, Western Psychiatric Institute  
 1995 National Institute on Drug Abuse (NIDA) Director's Award, travel fellowship for CPDD annual meeting  
 1997 Experimental Biology Summer Research Conference, Travel Fellowship  
 1998 ACNP/NIMH, travel fellowship for ACNP annual meeting  
 1998 College on the Problems of Drug Dependence (CPDD), travel fellowship for CPDD annual meeting  
 1998-2000 Society for Neuroscience, Neuroscience Scholars Program  
 2001 ASPET, Minority Young Scientist Travel Award  
 2005 NIDA, American Psychological Association, Early Career Investigator Award  
 2008 UCLA, Dr. Robert M. Stevenson Faculty-in-Residence Award, 2008  
 2008 CPDD International Committee, Targeted Expert Meeting on Addiction, travel fellowship for European College of Neuropsychopharmacology annual meeting  
 2009- 2014 Board of Directors, CPDD  
 2009 Texas A&M University-Commerce, Distinguished Alumnus  
 2009 National Academy of Sciences, Kavli fellow  
 2012- 2013 President, CPDD

#### Research Grants Currently Funded:

1. National Cancer Institute, 3P30CA125123-08S2, 2014-2015, "Inpatient & Outpatient Evaluation: Effects of E-Cigarettes in Nicotine-Dependent Cigarette Smokers", PI: R. De La Garza. *This is a supplement to the BCM Cancer Center grant to evaluate the effects of E-cigarettes as compared to own cigarettes during abstinence using neuroimaging and virtual reality.* \$372,410 direct costs.
2. Department of Veterans Affairs, 2014-2019, "Multimodal Imaging of Reward Brain Centers in Tobacco Smoking". PI: R. Salas, Co-I: R. De La Garza. *This study will use brain imaging and genetics to define the neural mechanisms and possible therapeutic targets for tobacco addiction in veterans.* \$946,846 direct costs.
3. National Institute on Drug Abuse, R25DA28976, 2011-2016, "Clinical Research Education for Drug Abuse Professionals", PI: T.F. Newton, Co-I: R. De La Garza. *This is a training grant aimed at increasing the number of researchers conducting translational research in addiction.* \$1,540,422 direct costs.
4. National Institute on Alcohol and Alcoholism, 1R42AA022049-01, 2013-2014, "Carisbamate Treatment for Alcohol Dependence", PI: T.F. Newton, Co-I: R. De La Garza. *This study will evaluate the novel compound carisbimate for alcohol dependence.* \$265,964 direct costs.
5. National Institute on Drug Abuse, R01DA035513-01A1, 2015-2018, "Complementary Combination Therapy for Cocaine Dependence", PI: T.F. Newton, Co-I: R. De La Garza. *This study will evaluate the effects of modafinil plus doxazosin on the reinforcing effects of cocaine in cocaine-dependent participants.*

#### Research Grants Completed:

1. National Institute on Drug Abuse, 1F31 DA05638, 1994-1996, "5-HT1A and 5-HT3 Receptor Modulation of Cocaine Behavior", PI: R. De La Garza. *The goal of this project was to establish the role of serotonergic*

- compounds in modulating the behavioral effects produced by cocaine in rats.*
2. National Institute on Mental Health 5T32 MH14275, 1996-1998, "Harvard Medical School Institutional Training Grant", PI: B.K. Madras. *This program provided postdoctoral training for individuals with specific interests in drug abuse research.*
  3. National Institute on Drug Abuse, 1F32 DA05857, 1998-1999, "Dopamine System Modulation by Cocaine Replacements", PI: R. De La Garza. *The goal of this project was to establish the role of novel cocaine medications (including nonamines) on dopamine system functioning in non-human primates.* \$24,800 direct costs.
  4. National Institute on Drug Abuse, 1R03 DA15126, 2001-2003, "Depression Enhances Vulnerability to Cocaine Relapse", PI: R. De La Garza. *The goal of this project was to determine the extent to which depressive-like behavior in rodents modulates cocaine seeking behavior and relapse to cocaine.* \$50,000 direct costs.
  5. National Institute on Drug Abuse, 1R21 DA023588, 2007-2010, "Cycloserine Enhancement of Extinction Learning", PI: R. De La Garza. *This study examined the effects of treatment with d-cycloserine for facilitating extinction of craving provoked by exposure to cigarette smoking cues.* \$275,000 direct costs.
  6. National Institute on Drug Abuse, NIDA-CPU-Lofexidine-0001, 2010-2012, "Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine", Co-PIs: R. De La Garza and G. Galloway. *This clinical pharmacology study assessed potential interactions between intravenous cocaine and treatment with lofexidine.* \$160,818 direct costs.
  7. National Institute on Drug Abuse, 1R01 DA023964, 2008-2012, "Rivastigmine as a Treatment for Methamphetamine Dependence", PI: R. De La Garza. *This study examined effects of treatment with rivastigmine on craving produced by experimental administration of methamphetamine in non-treatment-seeking METH-dependent volunteers.* \$749,820 direct costs.
  8. National Institute on Drug Abuse, 1RC1 DA028387, 2009-2012, "Modafinil and Escitalopram for Cocaine Dependence", PI: R. De La Garza. *This study evaluated the effects of treatment with modafinil plus the SSRI escitalopram on the subjective and reinforcing effects produced by smoked cocaine in the laboratory.* \$479,007 direct costs.
  9. National Institute on Drug Abuse, 1R01 DA027134, 2009-2012, "Varenicline as a Treatment for Methamphetamine Dependence", PI: R. De La Garza. *This study evaluated the preliminary efficacy of varenicline in non-treatment-seeking METH-dependent volunteers.* \$737,575 direct costs.
  10. National Institute on Drug Abuse, 3R01 DA023624-03S1, 2011-2012, "Rivastigmine and Huperzine A as Treatments for Cocaine Dependence", PI: R. De La Garza. *This was a supplement to the parent grant to examine changes to cardiovascular measures, body temperature, and movement following administration of these doses of cocaine utilizing a portable remote physiological monitoring device.* \$81,785 direct costs.
  11. National Institute on Drug Abuse, 1R01 DA023624, 2009-2013, "Rivastigmine and Huperzine A as Potential Treatments for Cocaine Addiction", PI: R. De La Garza. *This study evaluated the effects of rivastigmine or huperzine A on craving and reinforcing effects of cocaine in cocaine-dependent participants.* \$1,242,429 direct costs.
  12. Michael E. DeBaKey VAMC - Traumatic Brain Injury Center of Excellence, TBI COE Pilot Project, 2010-2013, "Virtual Reality Based Relapse Prevention for Alcohol Dependence in Veterans With Post-Traumatic Stress Disorder and/or Traumatic Brain Injury", PI: R. De La Garza. *This study determined the efficacy of virtual reality relapse prevention treatment in an open label trial with alcohol-abuse or dependent veterans with Post-traumatic Stress Disorder/Traumatic Brain Injury.* \$60,000 direct costs.
  13. Helix Medical Research Foundations, 2011-2014, "Genomic, Neural, Preclinical Analysis for Smoking Cessation", Co-PI's -T.R. Kosten, J. Dani, Co-I - R. De La Garza. *This was an inter-disciplinary and translational program to explore the genetic and neuronal underpinnings of nicotine dependence.* \$99,676 direct costs.
  14. National Institute on Drug Abuse, P50 DA018197, 2009-2014, "Stimulant Pharmacotherapy: Noradrenergic Targets", PI: T.R. Kosten, Co-I: R. De La Garza. *This study involved inpatient and outpatient clinical evaluations of compounds that target NE systems as treatment for cocaine and methamphetamine dependence.* \$1,613,804 direct costs.
  15. National Institute on Drug Abuse, 1 R21 DA030722, 2011-2014. "Exercise as a Behavioral Treatment for Cocaine Dependence", PI: R. De La Garza. *This study evaluated the effects of running versus walking on cocaine and nicotine craving and use in non-treatment-seeking cocaine-dependent cigarette smokers.* \$275,000 direct costs.
  16. National Institute on Drug Abuse, 1R01DA030241, 2010-2014, "Inter-Temporal Trade-offs in the Risky Decisions of Cocaine", Co-PIs: W. Bickel and R. Montague, Co-I: R. De La Garza. *This study used a model-based*

*approach, behavioral tasks, and functional MRI to uncover the behavioral and neural underpinnings of the pathological decisions in cocaine-dependent participants.*

17. MEDVAMC Research Enhancement Seed Grant, 2014, "Safety and Effectiveness of E-cigarettes for Smoking Cessation in Veterans", Co-PIs: R. De La Garza and D. Graham. *This study evaluated the effectiveness of e-cigarettes versus NRT on cigarette smoking, withdrawal, and craving.* \$50,000 direct costs.
18. Baylor College of Medicine Computational and Integrative Biomedical Research Center Seed Grant Award, 2014, "Modulating Craving States in Cocaine Addiction via Real-time fMRI Feedback", Co-PIs: R. De La Garza and D. Eagleman. *This study established a method for using real-time fMRI to help cocaine dependent participants control cravings for cocaine.* \$30,000 direct costs.

#### **Biomedical Journals - Ad hoc Reviewer:**

Psychopharmacology, Neuropsychopharmacology, Pharmacology Biochemistry and Behavior, Journal of Neuroscience Methods, Neuroscience, Drug and Alcohol Dependence, American Journal on Addictions, Progress in Neuropsychopharmacology and Biological Psychiatry, Journal of Psychiatric Practice, Journal of Studies on Alcohol and Drugs, Journal of Medicinal Chemistry, Addiction, Journal of Clinical Pharmacology, Biological Psychiatry, Brain Research, Psychoneuroendocrinology, Brain Behavior and Immunity, Substance Abuse Treatment Prevention and Policy, The Pharmacogenomics Journal, Neurochemical Research, Journal of Neurochemistry, Journal of Neural Transmission, Neuroscience Letters, Experimental and Clinical Psychopharmacology, Behavioural Brain Research, Journal of Neuroinflammation, Brain Behavior and Immunity.

#### **NIH and other National Review Panels:**

1. Appointed full member, Biobehavioral Mechanisms of Emotion, Stress and Health (MESH) (Oct 2009-June 2013).
2. NIH Scientific Review Group MESH, October 2006, June 2007, February 2008, June 2009.
3. Program Merit Review for Department of Veterans' Affairs, February 2007.
4. NIH Special Emphasis Panel, ZRG BBBP-C, June 2008.
5. NIH Special Emphasis Panel, ZRG1 IFCN-L-50 R, June 2009.
6. NIH Special Emphasis Panel, ZRG1 BBBP-J (95) S, June 2009.
7. NIH Special Emphasis Panel, ZRG1 BBBP-T (02) M & (97) S, July 2009.
8. NIH Special Emphasis Panel, ZDA1 GXM-A (03) 1, February 2011.
9. NIH Special Emphasis Panel, ZRG1 BDCN-M (02) M, March 2011.
10. NIH Special Emphasis Panel, 2012/02 PMDA, February 2012.
11. NIH Special Emphasis Panel, 2012/10 ZDA1 EXL-T (07) 1, June 2012.
12. NIH Special Emphasis Panel, ZRG1 BBBP-J 92, October 2012.
13. NIH Special Emphasis Panel, ZDA1 EXL-T(15) 1, December 2012.
14. NIH Special Emphasis Panel, BBBP-D02, July 2013.
15. NIH Special Emphasis Panel, BBBP-D04 0114, November 2013.
16. NIH Special Emphasis Panel, 2014/10 ZDA1 NXR-B (11) S, July 2014.
17. NIH Special Emphasis Panel, 2014/10 ZDA1 NXR-B (07) R, July 2014.
18. NIH Special Emphasis Panel, 2015/01 ZDA1 JXR-D (10) S, November 2014.
19. NIH Special Emphasis Panel, 2015/01 ZDA1 JXR-D (08) S, November 2014.
20. NIH Special Emphasis Panel, ZDA1 JXR-D(11), March 2015

#### **Membership and Service in Scientific Societies:**

1. College on Problems of Drug Dependence 1996-present
  - Fellow, 2012 - present
  - President, 2012-2013
  - Member, Executive Committee, 2011-2014
  - Board of Directors, 2008-2012
    - Chair, Long Range Planning Committee, 2014
    - Chair, Executive Officer Search Committee, 2012-2013
    - Chair, Nominations Committee, 2012
      - Member, Nominations Committee, 2006, 2008
    - Chair, *In Memoriam* Committee, 2011, 2012

- Chair, Publications Committee, 2006-2009
- Member, Publications Committee, 2004-2010
- Member, Under-Represented Populations Committee, 2006-2009
- Member, Animals in Research Committee, 2001-2004
- 2. American College of Neuropsychopharmacology, 2010-*present*
  - Regular Member, 2015-*present*
  - Associate Member, 2010-2014
  - Member, Education and Training Committee, 2014-2016
    - Member, Minority Sub-Committee, 2014
  - Member, Minority Task Force, 2013-2016
  - Mentor for Travel Awardees, 2011, 2012, 2013, 2014
- 3. National Hispanic Science Network on Drug Abuse, 2010-*present*
  - National Steering Committee, 2013-*present*
  - Co-Chair, Conference Planning Committee, 2014-2015
    - Member, Conference Planning Committee, 2014
  - Co-Chair, Fundraising Committee, 2014-2016
  - Co-Chair, Membership Committee, 2014-2016
  - Member, Program Committee, 2013
- 4. Society for Research on Nicotine and Tobacco, 2008-*present*
  - Member, 2008-*present*
  - Invited Abstract Reviewer for Program Committee, 2013, 2014
- 5. American Society for Pharmacology and Experimental Therapeutics, 2000-*present*
  - Member, Behavioral Pharmacology subdivision, 2000-*present*
  - Member, Neuropharmacology subdivision, 2000-*present*
  - Member, Committee on Minorities 2000-2005
    - Chair, Sub-Committee, Graduate Student Travel Awards, 2002-2005
- 6. Member, International Study Group Investigating Drugs as Reinforcers, 2001-*present*
- 7. Member, Society for Neuroscience, 1991-*present*
- 8. Member, Behavioral Pharmacology Society, 2003-2005
- 9. Member, Society of Biological Psychiatry, 2003-2005
- 10. Member, Society for Advancement of Chicano and Native Americans in Science, 1998-2000
- 11. Member, Speaker's Bureau, Massachusetts Society for Medical Research, 1997-1999
- 12. Member, Society on the Stimulus Properties on Drugs, 1994-1999
- 13. Co-Chair, Student's Chapter of the Texas Society for Biomedical Research, 1991-1996

#### **Invited Lectures and Oral Presentations:**

1. "Cocaine interactions with serotonin 5-HT<sub>3</sub> and dopamine receptors: Studies of the 5-HT<sub>3</sub> agonist 1-(*meta*-chlorophenyl)-biguanide as a discriminative stimulus in the rat. Oral presentation given at the College on Problems of Drug Dependence (CPDD), Palm Beach, FL, June, 1994.
2. "Neuropharmacological Analysis of the Effects Produced by Cocaine". Invited lecture given at Framingham State College, MA, April 24, 1997.
3. "Neurobiological Basis of Addiction". Invited lecture given at The Education Cooperative Summer Institute, Boston, MA, July 7, 1997.
4. "Necessity of Biomedical Research vs. Animal Rights". Invited debate versus Executive Director of New England Anti-Vivisectionist Society held at Wachusett H.S., Holden, MA, October 23, 1997.
5. "The Importance of the Use of Animals in Biomedical Research". Multiple presentations given over time through Massachusetts Society for Medical Research at Dracut H.S., Fall Brook J.H.S., Framingham H.S., Newton North H.S., 1997-1999.
6. "Autoradiography with [<sup>3</sup>H]U-101,958 and [<sup>3</sup>H]LU-85,295 Reveals High Densities of the D<sub>4</sub> Receptor in Cortical Regions and Hippocampus". Invited seminar given to the Neuroscience Group at McLean Hospital, Harvard Medical School, Belmont, MA, January 12, 1999.
7. "D<sub>4</sub> Dopamine Receptors, Labeled by [<sup>3</sup>H]U-101,958, Are Dense in Prefrontal Cortex and Hippocampus: Implications for "Novelty-Seeking" Behaviors and Psychostimulant Actions". Invited presentation given to the

- Department of Pharmaceutical Sciences at Northeastern University, Boston, MA, Feb 4, 1999.
8. "Developing a Co-Morbid Model of Depression and Liability to Stimulant Abuse". Invited presentation given to the Department of Neuroscience at Baylor University, Waco, TX, September 20, 2001.
  9. "A Co-Morbid Model of Depression and Liability to Nicotine Abuse". Invited presentation given to the Department of Psychology at Tufts University, Medford, MA, December 3, 2001.
  10. "Localization of Dopamine D4 Receptors in Brain: Distribution Profile in Monkeys, Mice and Man". Invited symposium speaker, Society for Neurochemistry 2002. *J. Neurochem.* 81 (suppl 1) 33.
  11. "Stress or Depression as Liability Factors for Nicotine Abuse". Invited presentation given to the Department of Psychology at Rutgers University, New Brunswick, NJ, February 28, 2003.
  12. "The Importance of Networking: Establishing Lifelines for Long-Term Survival". Invited symposium speaker Practical Tips for Success in a Pharmacology Graduate Program at the annual meeting of ASPET, April 2003.
  13. "Securing Your Future Through Competitive Grant Writing: Funding at the Postdoctoral Level". Invited symposium speaker Practical Tips for Success in a Pharmacology Graduate Program at the annual meeting of ASPET, April 2003.
  14. "Altered corticolimbic dopamine and serotonin turnover following repeated treatment with ( $\pm$ ) 3,4-MDMA ("Ecstasy"). Oral presentation given at the annual meeting of CPDD, Bal Harbour, FL, June 2003.
  15. "A Role for NSAIDs in Attenuating Lipopolysaccharide-induced Alterations to Reward Behavior, Corticosterone Release, and Pro-inflammatory Cytokine Activation". Invited presentation given to the Department of Physiology and Pharmacology at the City University of New York Medical School, New York, NY, September 10, 2003.
  16. "Lipopolysaccharide-induced Alterations to Basic Reward Behavior, Pro-inflammatory Cytokine Release, and HPA Axis Activation: Developing a Model of Immune System Activation as a Liability Factor for Substance Abuse and Relapse". Invited presentation given to the Center for Substance Abuse Research at the Temple University School of Medicine, Philadelphia, PA, November 20, 2003.
  17. "The Role of Immune System Activation as a Liability Factor for Substance Abuse in Humans". Invited presentation given to the Department of Psychiatry at the University of California at Los Angeles (UCLA), February 5, 2004.
  18. "Immune System Activation as a Liability Factor for Relapse to Substance Abuse". Invited lecture given to the Department of Pharmacology at the University of Texas Medical Branch, Galveston, TX, March 21, 2004.
  19. "The Role of Stress and Immune System Activation in Drug Addiction". Invited lecture given to the Department of Pharmacology, University of Colorado, Denver, CO, August 2004.
  20. "Neurobiological Consequences of MDMA Exposure: A 21<sup>st</sup> Century Framework". Chair of Invited mini-symposium presented at the annual meeting of the Society for Neuroscience, San Diego, CA, October 2004.
  21. "Methamphetamine Addiction and Treatment". Invited seminar given to the Neuroscience Group at McLean Hospital, Belmont, MA, Harvard Medical School, November 2, 2004.
  22. "Making a Difference in the Lives of Young People". Invited Commencement Address given to graduate school graduates of Texas A&M Commerce, Commerce, TX, August 13, 2005.
  23. "The Importance of Individual Variability in Establishing Profiles of Addiction". Invited seminar given to the Biology of Addictive Diseases Lab at Rockefeller University, New York, NY, November 18, 2005.
  24. "An Evaluation of the Effects of the Acetylcholinesterase Inhibitor Rivastigmine on Intravenous Self-Administration of Methamphetamine in Methamphetamine-Addicted Humans". Oral presentation given to the annual meeting of the International Study Group Investigating Drugs as Reinforcers (ISGIDAR), Scottsdale, AZ, June 17, 2006.
  25. "Individualizing Treatment for Methamphetamine Addiction: Why Unique Profiles of Addiction Are More Important Than Group Means". Invited seminar given at Marquette University, Milwaukee, WI, July 24, 2006.
  26. "The Neurobiological Basis of Drug Addiction". Invited lecture given to the Department of Biological Sciences and Sigma Xi Society at Texas A&M Commerce, Commerce, TX, September 29, 2006.
  27. "A Review of Methamphetamine Addiction and Current Pharmacological Treatment Approaches". Invited lecture given at the American Academy of Addiction Psychiatry Update conference, Ft. Worth, TX, September 30, 2006.
  28. "A Preliminary Analysis of the Impact of GVG Treatment on Methamphetamine Self-Administration and Subjective Effects in Methamphetamine-Dependent Participants". Oral presentation given at the annual meeting of ISGIDAR, Quebec City, Canada, June 16, 2007.
  29. "Tratamientos farmacológicos y psicologicos actuales y las perspectivas de tratamiento a futuro para la dependencia a metanfetamina y otros esmulantes anfetaminicos". Invited lecture given at El Congreso Internacional

- de Centros de Integracion Juvenil, Mexico City, Mexico, October 25, 2007.
30. "Acetylcholinesterase Inhibitors as Treatments for Methamphetamine-Dependence". Invited lecture given at the University of California Santa Barbara, January 18, 2008.
  31. "Acetylcholine and addiction: Neuropsychopharmacology studies in cocaine-, methamphetamine- and nicotine-dependent volunteers". Invited lecture for University of Texas MD Anderson Cancer Center (MDACC) Department of Behavioral Sciences, October 20, 2008.
  32. "Medications Development for Stimulant Addiction: Acetylcholine as a System of Interest". Invited lecture given at the Johns Hopkins School of Medicine, Behavioral Pharmacology Research Unit, October 29, 2008.
  33. "Identification and Testing of Novel Medications for Cocaine- and Methamphetamine-Addiction". Invited Grand Rounds lecture, BCM, Menninger Department of Psychiatry, January 14, 2009.
  34. "The Neurobiological Basis of Drug Addiction". Invited Grand Rounds lecture at MEDVAMC for BCM Department of Medicine, February 2, 2009.
  35. "AChE Inhibitors as Treatments for Methamphetamine Addiction". Invited lecture, BCM Clinical Pharmacology Consortium, September 2, 2009.
  36. "Clinical Neuroscience of Nicotine Dependence". Invited lecture, Dan L. Duncan Cancer Center Annual Symposium, Baylor College of Medicine, November 19, 2009.
  37. "Drug Abuse and Addiction in Adolescents". Invited lecture, Baylor College of Medicine, Menninger Department of Psychiatry, Psychiatry Update Symposium, December 5, 2009.
  38. "The Long and Winding Road to Medications Development and Testing for Stimulant Dependence". Invited workshop, Interdisciplinary Research Training Institute on Drug Abuse, University of Houston, June 5, 2010.
  39. "Money Matters: Self-administration of Methamphetamine in Methamphetamine-dependent Participants". Oral presentation given at the annual meeting of ISGIDAR, Scottsdale, AZ, June 2010.
  40. "Impulsivity + Craving = Drug Use?" Oral presentation given at the annual meeting of CPDD, Scottsdale, AZ, June 2010.
  41. "Snus: An Understudied Carcinogenic Agent". Invited presentation for MDACC Department of Psychiatry Educational Lecture Series, June 22, 2010.
  42. "A Role for Acetylcholine in Stimulant Abuse Disorders". Chair and speaker of invited Oral Symposium. Translational Research in Psychiatry Conference, Innsbruck AUSTRIA, July 9, 2010.
  43. Invited presentation for the Texas Regional Psychiatry Minority Mentor Network Retreat, August 28, 2010, Houston, TX.
  44. "Evaluating Drug Combinations for Cocaine Dependence". Invited presentation given at Wake Forest University School of Medicine, Department of Physiology and Pharmacology, April 11, 2011.
  45. "Subregion Specific Striatal Activity During Reward and Disappointment". Fast-breaking abstract oral presentation given at the annual meeting of CPDD, Hollywood, FL, June 2011.
  46. "Novel Pharmacotherapies for Stimulant Dependence". Invited lecture for NIDA International Forum - Building International Collaborative Research on Drug Abuse, given at the annual meeting of CPDD, Hollywood, FL, June 2011.
  47. "Negative Affective States and Addiction". Co-Chair and invited speaker at the annual meeting of the National Hispanic Science Network (NHSN), Miami, FL, August 2011.
  48. "Designing Interventions for Addiction". Invited panel speaker at the annual meeting of NHSN, Miami, FL, August 2011.
  49. "Medication Combos for Treating Stimulant Dependence". Invited Grand Rounds lecture for BCM Menninger Department of Psychiatry, November 2, 2011.
  50. "Do Antidepressants, Antipsychotics and other Medications Cause Psychiatric Adverse Events or Suicide?" Invited lecture for MDACC Department of Psychiatry Educational Lecture Series, January 25, 2012.
  51. "Pharmacotherapy for Opioid and Cocaine Dependence". Invited speaker for the South Carolina Psychiatric Association Meeting, Charleston, SC, January 28, 2012.
  52. "Lifelong Battle Against Depression & Addiction". Invited panelist Partnership Luncheon Houston Junior League, March 6, 2012.
  53. "Novel Approaches to Medications Development for Addiction". Invited lecture given to the Department of Physiology at Louisiana State University Health Sciences Center, New Orleans, LA, March 29, 2012.
  54. "Neuroadaptations Involved in Addiction and New Treatments Based Upon Mechanistic Advances". Featured Speaker and member of panel of experts for "Reel Science" sponsored by the UTMB Center for Addiction



Research and Organization of Postdoctoral Scientists, Galveston, TX, April 19, 2012.

55. "Individual Differences in Addiction Profiles and Medications Response". Invited symposium speaker at the annual meeting of ASPET, April 24, 2012.
56. "Polypharmacotherapeutic Approaches to Treating Stimulant Addiction". Invited lecture given to the Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, May 7, 2012.
57. "Career Development: A Perspective from Junior and Senior Researchers". Invited symposium speaker given at the annual meeting of CPDD, Palm Springs, CA, June 2012.
58. "Exercise as a Behavioral Treatment for Cocaine- and Nicotine-Dependence". Co-Chair and symposium speaker given at the annual meeting of CPDD, Palm Springs, CA, June 2012.
59. "Bench to Bedside - Following the Trail of Two Medications for Stimulant Dependence". Invited speaker for the symposium on *Current Status of Translational Pharmacotherapeutics for Addiction* for the annual meeting of NHSN, San Diego, CA, September 27, 2012.
60. "Novel Approaches to Medication Development for the Treatment of Addiction". Invited speaker for Advances in Clinical Psychiatry 2012, Baylor College of Medicine, September 21, 2012.
61. "Magic Bullets and Medication Compliance: Rethinking Medications Testing for Stimulant Dependence". Invited lecture given to the Department of Pharmacology, University of Houston, November 7, 2012.
62. Invited presentation on Addiction Neuroscience to students at The Kinkaid School, Houston, TX, November 19, 2012.
63. Invited presentation on Adolescence, The Developing Brain and Addiction to parents of students at The Kinkaid School, Houston, TX, November 27, 2012.
64. "Pharmacological and Behavioral Approaches to Medications Development for Stimulant Addiction". Invited Grand Rounds lecture for the University of Texas Health Sciences Center, Department of Psychiatry, January 16, 2013.
65. "Evaluating Noradrenergic Compounds as Treatments for Stimulant Dependence". Invited lecture given for the Fourth Annual University of Texas Psychiatry Update, Memorial Hermann Hospital Conference Center, February 9, 2013.
66. "NIH Funding for Addiction Research". Invited lecture given to faculty and trainees at the Universidad Peruana Cayetano Heredia, Lima, PERU, April 4, 2013.
67. "Addiction Neuroscience". Invited presentation given to students at The Kinkaid School, Houston, April 29, 2013.
68. "Varenicline as a Potential Treatment for Methamphetamine, Cocaine and Nicotine Addiction". Invited lecture given at the Johns Hopkins School of Medicine, Behavioral Pharmacology Research Unit, May 15, 2013.
69. "Laboratory and Community-based Evaluations of E-cigarette Initiation, Use and Perceptions in Cigarette Smokers". Invited lecture for MDACC Psychiatry Educational Lecture Series, August 21, 2013.
70. "Neurobiology of Suicide and Depression". Invited lecture for Dr. Ruth Ann White Day at Texas A&M Commerce, November 15, 2013.
71. Invited presentation on Addiction to students at Commerce High School, Commerce, TX, November 15, 2013.
72. "Virtual Reality-Induced Craving for Cigarettes Among Abstinent Smokers". Invited lecture for MDACC Psychiatry Educational Lecture Series, December 18, 2013.
73. "Polysubstance Abuse in Humans Necessitates Appropriate Animal Models". Invited lecture and Co-Chair of symposium on Animal Models of Polydrug Abuse given at the annual meeting of ASPET, April 27, 2014.
74. "Pharmacological and Behavioral Treatment Approaches for Drug Use Disorders". Invited lecture given at the Johns Hopkins School of Medicine, Behavioral Pharmacology Research Unit, May 22, 2014.
75. "Evaluation of Lisdexamfetamine Alone and Lisdexamfetamine + Modafinil for Cocaine Use Disorder". Oral presentation given at the annual meeting of CPDD, San Juan, Puerto Rico, June, 2014.
76. "Pharmacological Treatment Approaches for Cocaine and Methamphetamine Use Disorders". Invited plenary lecture for symposium on Motivated Behaviors and Neuroplasticity: Role in Addiction given at the Latin American Research Network in Drug Addiction (LARNEDA) meeting, San Juan, Puerto Rico, November, 2014.
77. "Psychiatric Symptoms in Cancer Patients: An Overview of Key Findings from the First 500 Patients Enrolled in the PsychCare Electronic Database". Invited lecture for MDACC Department of Psychiatry Educational Lecture Series, March 18, 2015.
78. "Subjective, Reinforcing and Cognitive Effects of Methamphetamine in Humans". Invited lecture for symposium on Psychomotor Stimulant Addiction: Lessons from Methamphetamine to be given at the annual meeting of

ASPET, Boston, MA, March 30, 2015.

79. “Neurobiological, Genetic and Environmental Factors Contributing to Adolescent Drug Use”. Invited lecture for Pediatric Neurology Grand Rounds at Texas Children’s Hospital, July 22, 2015.

#### **Bibliography: Original Articles (Peer-reviewed)**

1. Callahan PM, **De La Garza R 2nd**, Cunningham KA. Discriminative stimulus properties of cocaine: modulation by dopamine D1 receptors in the nucleus accumbens. *Psychopharmacology (Berl)*. 1994 Jun;115(1-2):110-4, PMID: [7862881](#).
2. **De La Garza R 2nd**, Callahan PM, Cunningham KA. Detailed investigations of 5-HT<sub>3</sub> compounds in a drug discrimination model. *Pharmacol Biochem Behav*. 1996 Jul;54(3):533-40, PMID: [8743626](#).
3. Callahan PM, **De La Garza R 2nd**, Cunningham KA. Mediation of the discriminative stimulus properties of cocaine by mesocorticolimbic dopamine systems. *Pharmacol Biochem Behav*. 1997 Jul;57(3):601-7, PMID: [9218282](#).
4. **De La Garza R 2nd**, Callahan PM, Cunningham KA. The discriminative stimulus properties of cocaine: effects of microinfusion of cocaine, a 5-HT<sub>1A</sub> agonist or antagonist, into the ventral tegmental area. *Psychopharmacology (Berl)*. 1998 May;137(1):1-6, PMID: [9631950](#).
5. **De La Garza R 2nd**, Meltzer PC, Madras BK. Non-amine dopamine transporter probe [(3)H]tropoxene distributes to dopamine-rich regions of monkey brain. *Synapse*. 1999 Oct;34(1):20-7, PMID: [10459168](#).
6. **De La Garza R 2nd**, Cunningham KA. The effects of the 5-hydroxytryptamine(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. *J Pharmacol Exp Ther*. 2000 Feb;292(2):610-7, PMID: [10640298](#).
7. **De La Garza R 2nd**, Madras BK. [(3)H]PNU-101958, a D(4) dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. *Synapse*. 2000 Sep 1;37(3):232-44, PMID: [10881045](#).
8. Miller GM, **De La Garza R 2nd**, Novak MA, Madras BK. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders. *Mol Psychiatry*. 2001 Jan;6(1):50-8, PMID: [11244485](#).
9. Miller GM, Yatin SM, **De La Garza R 2nd**, Goulet M, Madras BK. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. *Brain Res Mol Brain Res*. 2001 Feb 19;87(1):124-43, PMID: [11223167](#).
10. Jentsch JD, Olausson P, **De La Garza R 2nd**, Taylor JR. Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys. *Neuropsychopharmacology*. 2002 Feb;26(2):183-90, PMID: [11790514](#).
11. **De La Garza R 2nd**, Jentsch JD, Verrico CD, Roth RH. Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine. *Brain Res*. 2002 Dec 20;958(1):20-7, PMID: [12468026](#).
12. Overstreet DH, Commissaris RC, **De La Garza R 2nd**, File SE, Knapp DJ, Seiden LS. Involvement of 5-HT<sub>1A</sub> receptors in animal tests of anxiety and depression: evidence from genetic models. *Stress*. 2003 Jun;6(2):101-10, PMID: [12775329](#).
13. Asnis GM, **De la Garza R 2nd**, Kohn SR, Reinus JF, Henderson M, Shah J. IFN-induced depression: a role for NSAIDs. *Psychopharmacol Bull*. 2003 Summer;37(3):29-50, PMID: [14608239](#).
14. **De La Garza R 2nd**, Asnis GM. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN- $\alpha$  induced alterations to monoamine turnover in prefrontal cortex and hippocampus. *Brain Res*. 2003 Jul 4;977(1):70-9, PMID: [12788515](#).
15. Madras BK, Fahey MA, Miller GM, **De La Garza R**, Goulet M, Spealman RD, Meltzer PC, George SR, O'Dowd BF, Bonab AA, Livni E, Fischman AJ. Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. *Eur J Pharmacol*. 2003 Oct 31;479(1-3):41-51, PMID: [14612136](#).
16. **De La Garza R 2nd**, Fabrizio KR, Radoi GE, Vlad T, Asnis GM. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release. *Behav Brain Res*. 2004 Feb 4;149(1):77-85, PMID: [14739012](#).
17. **De La Garza R 2nd**, Mahoney JJ 3rd. A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. *Brain Res*. 2004 Sep 24;1021(2):209-18, PMID: [15342269](#).
18. **De La Garza R 2nd**. Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of

- depression: focus on anhedonia. *Neurosci Biobehav Rev.* 2005;29(4-5):761-70, PMID: [15878621](#).
19. **De La Garza R 2nd**, Newton TF, Kalechstein AD. Risperidone diminishes cocaine-induced craving. *Psychopharmacology (Berl)*. 2005 Mar;178(2-3):347-50, PMID: [15452684](#).
  20. **De La Garza R 2nd**, Asnis GM, Fabrizio KR, Pedrosa E. Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats. *Psychopharmacology (Berl)*. 2005 May;179(2):356-65, PMID: [15565429](#).
  21. Asnis GM, **De La Garza R 2nd**. Interferon-induced depression: strategies in treatment. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005 Jun;29(5):808-18, PMID: [15907352](#).
  22. **De La Garza R 2nd**, Asnis GM, Pedrosa E, Stearns C, Migdal AL, Reinus JF, Paladugu R, Vemulapalli S. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005 Jun;29(5):781-92, PMID: [15927336](#).
  23. Fantegrossi WE, Kiessel CL, **De la Garza R 2nd**, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. *Psychopharmacology (Berl)*. 2005 Sep;181(3):529-36, PMID: [15983787](#).
  24. Newton TF, **De La Garza R 2nd**, Kalechstein AD, Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. *Pharmacol Biochem Behav.* 2005 Sep;82(1):90-7, PMID: [16112720](#).
  25. Newton TF, Kalechstein AD, **De La Garza R 2nd**, Cutting DJ, Ling W. Apathy predicts hedonic but not craving response to cocaine. *Pharmacol Biochem Behav.* 2005 Sep;82(1):236-40, PMID: [16181666](#).
  26. **De la Garza R 2nd**. Wistar Kyoto rats exhibit reduced sucrose pellet reinforcement behavior and intravenous nicotine self-administration. *Pharmacol Biochem Behav.* 2005 Oct;82(2):330-7, PMID: [16226802](#).
  27. Fong TW, **De La Garza R 2nd**, Newton TF. A case report of topiramate in the treatment of nonparaphilic sexual addiction. *J Clin Psychopharmacol.* 2005 Oct;25(5):512-4, PMID: [16160641](#).
  28. Newton TF, Roache JD, **De La Garza R 2nd**, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. Safety of intravenous methamphetamine administration during treatment with bupropion. *Psychopharmacology (Berl)*. 2005 Nov;182(3):426-35, PMID: [16163531](#).
  29. Newton TF, **De La Garza R 2nd**, Fong T, Chiang N, Holmes TH, Bloch DA, Anderson A, Elkashef A. A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. *Pharmacol Biochem Behav.* 2005 Dec;82(4):704-11, PMID: [16413604](#).
  30. Asnis GM, **De La Garza R 2nd**. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. *J Clin Gastroenterol.* 2006 Apr;40(4):322-35, PMID: [16633105](#).
  31. Newton TF, Roache JD, **De La Garza R 2nd**, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. *Neuropsychopharmacology.* 2006 Jul;31(7):1537-44, PMID: [16319910](#).
  32. **De La Garza R 2nd**, Fabrizio KR, Gupta A. Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. *Psychopharmacology (Berl)*. 2007 Jan;189(4):425-34, PMID: [16470404](#).
  33. Kalechstein AD, **De La Garza R 2nd**, Mahoney JJ 3rd, Fantegrossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. *Psychopharmacology (Berl)*. 2007 Jan;189(4):531-7, PMID: [17082969](#).
  34. Mahoney JJ 3rd, Kalechstein AD, **De La Garza R 2nd**, Newton TF. A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007 Apr 13;31(3):593-9, PMID: [17270333](#).
  35. Rotheram-Fuller E, **De La Garza R 2nd**, Mahoney JJ 3rd, Shoptaw S, Newton TF. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. *Psychiatry Res.* 2007 Aug 30;152(2-3):205-10, PMID: [17449110](#).
  36. Fantegrossi WE, Ciullo JR, Wakabayashi KT, **De La Garza R 2nd**, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. *Neuroscience.* 2008 Jan 24;151(2):533-43, PMID: [18082974](#).
  37. Mahoney JJ 3rd, Kalechstein AD, **De La Garza R 2nd**, Newton TF. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. *Am J Addict.* 2008 Mar-Apr;17(2):83-98, PMID: [18393050](#).
  38. Fleury G, **De La Garza R 2nd**, Mahoney JJ 3rd, Evans SE, Newton TF. Predictors of cardiovascular response to methamphetamine administration in methamphetamine-dependent individuals. *Am J Addict.* 2008 Mar-

- Apr;17(2):103-10, PMID: [18393052](#).
39. **De La Garza R 2nd**, Mahoney JJ 3rd, Culbertson C, Shoptaw S, Newton TF. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. *Pharmacol Biochem Behav.* 2008 Apr;89(2):200-8, PMID: [18207225](#).
  40. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, **De La Garza R**, Newton T, Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug Alcohol Depend.* 2008 Aug 1;96(3):222-32, PMID: [18468815](#).
  41. **De La Garza R**, Shoptaw S, Newton TF. Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. *Int J Neuropsychopharmacol.* 2008 Sep;11(6):729-41, PMID: [18248689](#).
  42. Newton TF, Reid MS, **De La Garza R**, Mahoney JJ, Abad A, Condos R, Palamar J, Halkitis PN, Mojisak J, Anderson A, Li SH, Elkashef A. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. *Int J Neuropsychopharmacol.* 2008 Dec;11(8):1037-45, PMID: [18664303](#).
  43. Culbertson C, **De La Garza R 2nd**, Costello M, Newton TF. Unrestricted access to methamphetamine or cocaine in the past is associated with increased current use. *Int J Neuropsychopharmacol.* 2009 Jun;12(5):677-85, PMID: [19220922](#).
  44. Kalechstein AD, **De la Garza R 2nd**, Newton TF, Green MF, Cook IA, Leuchter AF. Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals. *J Neuropsychiatry Clin Neurosci.* 2009 Summer;21(3):254-8, PMID: [19776303](#).
  45. Newton TF, **De La Garza R 2nd**, Kalechstein AD, Tziortzis D, Jacobsen CA. Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. *Am J Addict.* 2009 Jul-Aug;18(4):294-300, PMID: [19444733](#).
  46. **De La Garza R 2nd**, Zorick T, Heinzerling KG, Nusinowitz S, London ED, Shoptaw S, Moody DE, Newton TF. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. *Pharmacol Biochem Behav.* 2009 Nov;94(1):186-93, PMID: [19698734](#).
  47. **De La Garza R 2nd**, Ashbrook LH, Evans SE, Jacobsen CA, Kalechstein AD, Newton TF. Influence of verbal recall of a recent stress experience on anxiety and desire for cocaine in non-treatment seeking, cocaine-addicted volunteers. *Am J Addict.* 2009 Nov-Dec;18(6):481-7, PMID: [19874169](#).
  48. Zorick T, Sevak RJ, Miotto K, Shoptaw S, Swanson AN, Clement C, **De La Garza R 2nd**, Newton TF, London ED. Pilot Safety Evaluation of Varenicline for the Treatment of Methamphetamine Dependence. *J Exp Pharmacol.* 2009 Dec 1;2010(2):13-18, PMID: [20689642](#).
  49. **De La Garza R 2nd**, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. *Drug Alcohol Depend.* 2010 Jan 15;106(2-3):173-80, PMID: [19781865](#).
  50. Kalechstein AD, **De La Garza R 2nd**, Newton TF. Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment. *Am J Addict.* 2010 Jul-Aug;19(4):340-4, PMID: [20653641](#).
  51. Newton TF, **De La Garza R 2nd**, Grasing K. The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans. *Psychiatry Res.* 2010 Aug 30;179(1):96-100, PMID: [20493549](#).
  52. Culbertson C, Nicolas S, Zaharovits I, London ED, **De La Garza R 2nd**, Brody AL, Newton TF. Methamphetamine craving induced in an online virtual reality environment. *Pharmacol Biochem Behav.* 2010 Oct;96(4):454-60, PMID: [20643158](#).
  53. Mahoney JJ 3rd, Hawkins RY, **De La Garza R 2nd**, Kalechstein AD, Newton TF. Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. *Gend Med.* 2010 Oct;7(5):414-21, PMID: [21056868](#).
  54. Haile CN, **De La Garza R 2nd**, Newton TF. Methamphetamine Cured my Cocaine Addiction. *J Addict Res Ther.* 2010 Oct 14;1(103) 1000103, PMID: [23066512](#).
  55. Mahoney JJ 3rd, Jackson BJ, Kalechstein AD, **De La Garza R 2nd**, Newton TF. Acute, low-dose methamphetamine administration improves attention/information processing speed and working memory in

- methamphetamine-dependent individuals displaying poorer cognitive performance at baseline. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011 Mar 30;35(2):459-65, PMID: [21122811](#).
56. Tziortzis D, Mahoney JJ 3rd, Kalechstein AD, Newton TF, **De La Garza R 2nd**. The relationship between impulsivity and craving in cocaine- and methamphetamine-dependent volunteers. *Pharmacol Biochem Behav*. 2011 Apr;98(2):196-202, PMID: [21215769](#).
57. Kalechstein AD, Yoon JH, Croft DE, Jaeggi S, Mahoney JJ 3rd, **De La Garza R 2nd**. Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. *Pharmacol Biochem Behav*. 2011 Sep;99(3):423-7, PMID: [21624391](#).
58. **De la Garza R 2nd**, Yoon JH. Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011 Dec 1;35(8):1827-30, PMID: [21803113](#).
59. Roache JD, Kahn R, Newton TF, Wallace CL, Murff WL, **De La Garza R 2nd**, Rivera O, Anderson A, Mojsiak J, Elkashef A. A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. *Drug Alcohol Depend*. 2011 Dec 1;119(1-2):37-45, PMID: [21696894](#).
60. Newton TF, **De La Garza R 2nd**, Brown G, Kosten TR, Mahoney JJ 3rd, Haile CN. Noradrenergic  $\alpha_1$  receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. *PLoS One*. 2012;7(2):e30854, PMID: [22319592](#).
61. Haile CN, **De La Garza R 2nd**, Mahoney JJ 3rd, Nielsen DA, Kosten TR, Newton TF. The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. *PLoS One*. 2012;7(11):e47702, PMID: [23144826](#).
62. **De La Garza R 2nd**, Newton TF, Haile CN, Yoon JH, Nerumalla CS, Mahoney JJ 3rd, Aziziyeh A. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012 Apr 27;37(1):141-6, PMID: [22230648](#).
63. Haile CN, Mahoney JJ 3rd, Newton TF, **De La Garza R 2nd**. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. *Pharmacol Ther*. 2012 May;134(2):260-77, PMID: [22327234](#).
64. Mahoney JJ, Jackson BJ, Kalechstein AD, **De La Garza R 2nd**, Chang LC, Newton TF. Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. *Int J Neuropsychopharmacol*. 2012 Oct;15(9):1241-9, PMID: [22214752](#).
65. Kalechstein AD, Yoon JH, Mahoney JJ 3rd, Newton TF, Chang L, **De La Garza R 2nd**. d-Cycloserine administration does not affect neurocognition in concurrent cocaine- and nicotine-dependent volunteers. *Pharmacol Biochem Behav*. 2012 Dec;103(2):403-7, PMID: [22960612](#).
66. Culbertson C, Shulenberg S, **De La Garza R**, Newton TF, Brody AL (2012) Virtual Reality Cue Exposure Therapy for the Treatment of Tobacco Dependence. *Journal of Cybertherapy and Rehabilitation* 5: 57-64.
67. Mahoney, III, J.J., Jackson, B.J., Kalechstein, A.D., **De La Garza, II, R.**, Shah, R., Nerumalla, C.S., Newton, T.F. (2012) The effects of the benzodiazepine, temazepam, on neurocognitive functioning and sleep patterns in methamphetamine-dependent participants. *J Addict Res Ther* S1:007. doi:10.4172/2155-6105.S1-007.
68. Kalechstein AD, Mahoney JJ 3rd, Yoon JH, Bennett R, **De la Garza R 2nd**. Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. *Neuropharmacology*. 2013 Jan;64:472-8, PMID: [22796108](#).
69. Yoon JH, Newton TF, Haile CN, Bordnick PS, Fintzy RE, Culbertson C, Mahoney JJ 3rd, Hawkins RY, Labounty KR, Ross EL, Aziziyeh AI, **De La Garza R 2nd**. Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers. *Addict Behav*. 2013 Feb;38(2):1518-26, PMID: [22560371](#).
70. Brewer AJ 3rd, Mahoney JJ 3rd, Nerumalla CS, Newton TF, **De La Garza R 2nd**. The influence of smoking cigarettes on the high and desire for cocaine among active cocaine users. *Pharmacol Biochem Behav*. 2013 May;106:132-6, PMID: [23541494](#).
71. Mahoney JJ 3rd, Newton TF, Omar Y, Ross EL, **De la Garza R 2nd**. The relationship between lifetime stress and addiction severity in cocaine-dependent participants. *Eur Neuropsychopharmacol*. 2013 May;23(5):351-7, PMID: [22748418](#).
72. Chang LC, Mahoney JJ 3rd, Raty SR, Ortiz J, Apodaca S, **De La Garza R 2nd**. Neurocognitive effects following an overnight call shift on faculty anesthesiologists. *Acta Anaesthesiol Scand*. 2013 Sep;57(8):1051-7, PMID:

[23593975](#).

73. Ross EL, Yoon JH, Mahoney JJ 3rd, Omar Y, Newton TF, **De La Garza R 2nd**. The impact of self-reported life stress on current impulsivity in cocaine dependent adults. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013 Oct 1;46:113-9, PMID: [23796525](#).
74. Verrico CD, Haile CN, Newton TF, Kosten TR, **De La Garza R 2nd**. Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. *Expert Opin Investig Drugs*. 2013 Dec;22(12):1549-68, PMID: [24033127](#).
75. Haile CN, **De La Garza R 2nd**, Mahoney JJ 3rd, Newton TF. Effects of methamphetamine on the noradrenergic activity biomarker salivary alpha-amylase. *Drug Alcohol Depend*. 2013 Dec 1;133(2):759-62, PMID: [23968815](#).
76. Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ 3rd, **De La Garza R 2nd**, Charney DS, Newton TF, Mathew SJ. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. *Int J Neuropsychopharmacol*. 2014 Feb;17(2):331-6, PMID: [24103211](#).
77. Verrico CD, Mahoney JJ 3rd, Thompson-Lake DG, Bennett RS, Newton TF, **De La Garza R 2nd**. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. *Int J Neuropsychopharmacol*. 2014 Feb;17(2):223-33, PMID: [24393456](#).
78. Mahoney JJ 3rd, Kalechstein AD, Verrico CD, Arnoudse NM, Shapiro BA, **De La Garza R 2nd**. Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014 Apr 3;50:137-42, PMID: [24239594](#).
79. **De La Garza R 2nd**, Galloway GP, Newton TF, Mendelson J, Haile CN, Dib E, Hawkins RY, Chen CY, Mahoney JJ 3rd, Mojsiak J, Lao G, Anderson A, Kahn R. Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014 Apr 3;50:44-52, PMID: [24316175](#).
80. Yoon JH, Shah RS, Arnoudse NM, **De La Garza R 2nd**. Remote physiological monitoring of acute cocaine exposure. *J Med Eng Technol*. 2014 Jul;38(5):244-50, PMID: [24841843](#).
81. Spellacy CJ, Harding MJ, Hamon SC, Mahoney JJ 3rd, Reyes JA, Kosten TR, Newton TF, **De La Garza R 2nd**, Nielsen DA. A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study. *Genes Brain Behav*. 2014 Jul;13(6):559-64, PMID: [24528631](#).
82. Kalechstein AD, Mahoney JJ 3rd, Verrico CD, **De La Garza R 2nd**. Short-term, low-dose varenicline administration enhances information processing speed in methamphetamine-dependent users. *Neuropharmacology*. 2014 Oct;85:493-8, PMID: [24930359](#).
83. Mahoney JJ 3rd, **De La Garza R 2nd**, Jackson BJ, Verrico CD, Ho A, Iqbal T, Newton TF. The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. *Psychiatry Res*. 2014 Oct 30;219(2):367-71, PMID: [24951161](#).
84. Verrico, C.D., Haile, C.N., Mahoney, III, J.J., Thompson-Lake, D.G.Y., Newton, T.F., **De La Garza R 2nd**. Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: A randomized, double blind, placebo-controlled human laboratory study. *Drug Alcohol Depend*. 2014 Aug 1;141:72-8, PMID: [24928479](#).
85. Baeza-Loya, S., Viswanath, H., Carter, A., Molfese, D.L., Velasquez, K.M., Baldwin, P.R., Thompson-Lake, D.G.Y., Sharp, C., Fowler, J.C., **De La Garza, II, R.**, Salas, R. Perceptions about e-cigarette safety may lead into e-smoking during pregnancy. *Bull Menninger Clin*. 2014 Summer;78(3):243-52, PMID: [25247743](#).
86. Savjani, R.R., Velasquez, K.M., Thompson-Lake, D.G.Y., Eagleman, D.M., **De La Garza, II, R.**, Salas, R. Characterizing white matter changes in cigarette smokers via diffusion tensor imaging. *Drug Alcohol Depend*. 2014 Dec 1;145:134-42, PMID: [25457737](#).
87. Mahoney, III, J.J., Thompson-Lake, D.G.Y., Cooper, K., Verrico, C.D., Newton, T.F., **De La Garza, II, R.** A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders. *J Psychopharmacol*. 2015 Jan;29(1):50-6. PMID [25424624](#).
88. **De La Garza, II, R.**, Bubar, M.J., Carbone, C.L., Moeller, F.G., Newton, T.F., Anastasio, N.C., Harper, T.A., Ware, D.L., Fuller, M.A., Holstein, G.J., Jayroe, J.B., Bandak, S.I., Reiman, K.Z., Neale, A.C., Pickford, L.B., Cunningham, K.A. (2015) Evaluation of the dopamine beta-hydroxylase (D $\beta$ H) inhibitor nepicastat in participants who meet criteria for cocaine use disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 59: 40-48. PMID: [25602710](#).

89. Wesley MJ, Lohrenz T, Koffarnus MN, McClure SM, **De La Garza R 2nd**, Salas R, Thompson-Lake DG, Newton TF, Bickel WK, Montague PR. (2014) Choosing money over drugs: the neural underpinnings of difficult choice in chronic cocaine users. *J. Addiction (in press)*, PMID: [25197609](#).
90. Thompson-Lake, D.G.Y., Cooper, K.N., Mahoney, III, J.J., Bordnick, P.S., Salas, R., Kosten, T.R., Dani, J.A., **De La Garza, II, R.** (2014) Virtual reality cue-induced craving and withdrawal in abstinent cigarette smokers. *Nicotine & Tobacco Research (in press)*, PMID: [25475087](#).
91. Viswanath, H., Velasquez, K.M., Thompson-Lake, D.G.Y., Savjani, R., Carter, A.Q., Eagleman, D.M., Baldwin, P.R., **De La Garza, II, R.**, Salas, R. (2015) Alterations in interhemispheric functional and anatomical connectivity are associated with tobacco smoking in humans. *Frontiers Human Neuroscience (in press)*.
92. Brewer, A.J., III, Nielsen, D.A., Spellicy, C.J., Hamon, S.C., Gingrich, J., Nielsen, E.M., Mahoney, III, J.J., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** (2015) Genetic variants of the dopamine transporter (DAT1) influence the acute subjective responses to cocaine in cocaine-dependent volunteers. *Pharmacogenetics and Genomics (in press)*.
93. Christodoulides, N., **De La Garza, II, R.**, Simmons, G.W., McRae, M.P., Wong, J., Newton, T.F., Smith, R., Mahoney, III, J.J., Hohenstein, J., Gomez, S., Floriano, P.N., Talavera, H., Sloan, D.J., Moody, D.E., Andrenyak, D.M., Kosten, T.R., Haque, A., McDevitt, J.T. (2015) Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids. *Drug Alcohol Depend. (in press)*.
94. Asnis, G.M., Mujeed, K., Henderson, M.A., Sylvester, C., Thomas, M., **De La Garza, II, R.** (2015) Tinnitus comorbid with insomnia: a significant relationship and implications. *International Journal of Medical Science (under review)*.
95. Haile, C.N., Thompson-Lake, D.G.Y., Mahoney, III, J.J., Newton, T.F., **De La Garza, II, R.** (2015) Cocaine-induced subjective effects differ between African Americans and Caucasians. *Drug Alcohol Depend. (under review)*.
96. Shorter, D.I., Nielsen, D.A. Hamon, S., Nielsen, E., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** (2015) Alpha-1 adrenergic receptor (ADRA1A) genotype influences magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. *Pharmacogenetics and Genomics (under review)*.
97. Newton, T.F., Haile, C.N., Mahoney, J.J., Shah, R., **De La Garza, II, R.**, Kosten, T.R. (2015) Dopamine D3 receptor-preferring agonist enhances the positive subjective effects of cocaine in humans. *Drug Alcohol Depend. (under review)*.

#### Other Publications:

1. Asnis GM, **De La Garza R 2nd**, Miller AH, Raison CL. Ribavirin may be an important factor in IFN-induced neuropsychiatric effects. *J Clin Psychiatry*. 2004 Apr;65(4):581-2. (PMID: [15119925](#))
2. Asnis GM, **De La Garza R**, Rego SA, Henderson MA, Reinus JF. Interferon for hepatitis C patients with psychiatric disorders. *Am J Psychiatry*. 2004 Dec;161(12):2332-4. (PMID: [15569920](#))
3. **De La Garza, II, R.**, Asnis, G.M. (2006) In search of animal models of cytokine-induced depression. *Progr. Neuropsychopharm. Biol. Psych.* 30: 1366.
4. **De La Garza, II, R.**, Miczek, K.A. (2007) A contemporary view of MDMA. *Psychopharmacology* 189: 403-405.
5. Singh HH, Rapaka RS, Shurtleff D, **De La Garza R.** NIDA drug supply and analytical services program: providing research resources and tools to the scientific community. *Drug Alcohol Depend.* 2008 May 1;95(1-2):182-6. (PMID: [18484110](#))
6. Cinciripini, P.M., **De La Garza, II, R.** (2014) E-Cigarettes: Time to Regulate? *Medscape Pulmonary Medicine* (<http://www.medscape.com/viewarticle/820037>).
7. Christodoulides, N., **De La Garza, II, R.**, Simmons, GW, McRae, MP, Wong, J, Kosten, TR, Miller, CS, Ebersole, JL, McDevitt, JT. (2014) Programmable Bio-Nano-Chip System for Saliva Diagnostics. In: *Sensing Technologies for Global Health, Military Medicine, and Environmental Monitoring IV*. Eds: Southern, SO, Mentzer, MA, Rodriguez Chavez, I, Wotring, VE. Book Series: Proceedings of Society of Photo-Optical Instrumentation Engineers, Vol 9112, Article 911206, DOI: 10.1117/12.2058726, ISBN: 978-1-62841-049-5, (<http://proceedings.spiedigitallibrary.org/proceeding.aspx?articleid=1880667>).

#### Books and Book Chapters:

1. Cocaine and Methamphetamine Dependence – Advances in Treatment. American Psychiatric Association (APA: 2012). Edited by: T.R. Kosten, T.F. Newton, **R. De La Garza, II**, C.N. Haile.

2. Newton, T.F., **De La Garza, II, R.**, Kalechstein, A.D. “Pharmacotherapy”. In Cocaine and Methamphetamine Dependence – Advances in Treatment. APA (2012). Eds. Kosten, Newton, **De La Garza**, Haile.
3. **De La Garza, II, R.**, Kalechstein, A.D. “Polydrug Abuse”. In Cocaine and Methamphetamine Dependence – Advances in Treatment. APA (2012). Eds. Kosten, Newton, **De La Garza**, Haile.
4. T.R. Kosten, T.F. Newton, **R. De La Garza, II**, C.N. Haile. “Substance Use and Addictive Diseases”. Sixth Edition of the American Psychiatric Publishing Textbook of Psychiatry (March 2014).
5. T.R. Kosten, C.N. Haile, S.P. Woods, T.F. Newton, **R. De La Garza, II**. “Neuropsychiatry of Alcohol and Other Substance Use Disorders”. In Textbook of Neuropsychiatry and Behavioral Neurosciences, American Psychiatric Publishing (2015).

#### **Abstracts Presented at National and International Conferences:**

1. Callahan, P.M., **De La Garza II, R.**, Cunningham, K.A. Discriminative stimulus properties of cocaine: Modulation by dopamine D<sub>1</sub> receptors in the nucleus accumbens. Presented at the annual meeting of Experimental Biology and the American Society of Pharmacology and Experimental Therapeutics (ASPET). FASEB 7: A856, 1993.
2. Callahan, P.M., **De La Garza II, R.**, Bryan, S.K., Cunningham, K.A. Discriminative stimulus properties of cocaine: Modulation by dopamine D<sub>1</sub> receptors in the nucleus accumbens and amygdala. Paper presented at the Society for Neuroscience (SfN) Satellite Session - Society for the Stimulus Properties of Drugs, Washington, DC, November 1993.
3. **De La Garza II, R.**, Cunningham, K.A. Effects of the 5-HT<sub>3</sub> antagonist zacopride on the development and expression of sensitization. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 19: 1850, 1993.
4. **De La Garza II, R.**, Callahan, P.M., Cunningham, K.A. Cocaine interactions with serotonin 5-HT<sub>3</sub> and dopamine receptors: Studies of the 5-HT<sub>3</sub> agonist 1-(*meta*-chlorophenyl)-biguanide (mCPB) as a discriminative stimulus in the rat. Paper presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Beach, FL, June 1994.
5. Cunningham, K.A., Callahan, P.M., **De La Garza II, R.**, Windh, R.T. Pre- and Postsynaptic effects of cocaine on serotonin function: Neurophysiological and behavioral analyses. Paper presented at the third IUPHAR Satellite Meeting on Serotonin, Chicago, IL, July 1994.
6. Windh, R.T., **De La Garza II, R.**, Mah, E.J., Thomas, M.L., Cunningham, K.A. 5-HT<sub>1A</sub> receptor antisense oligonucleotide, MDMA and 8-OH-DPAT treatment effects on cocaine inhibition of dorsal raphe 5-HT cells. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 20: 1545, 1994.
7. **De La Garza II, R.**, Cunningham, K.A. 5-HT<sub>1A</sub> receptor modulation of the hyperactivity induced by acute cocaine administration. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 20: 1545, 1994.
8. Cunningham, K.A., Callahan, P.M., **De La Garza II, R.** Dopamine and serotonin as mediators of the discriminative stimulus effects of cocaine. Paper presented at the annual meeting of the American College of Neuropsychopharmacology (ACNP), Puerto Rico, December 1994.
9. **De La Garza II, R.**, Windh, R.T., Cunningham, K.A. 5-HT<sub>1A</sub> receptor modulation of the development and expression of cocaine-induced behavioral sensitization. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 1995.
10. **De La Garza II, R.**, Callahan, P.M., Cunningham, K.A. Role of the ventral tegmental area in the discriminative stimulus effects produced by cocaine. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 21: 711, 1995.
11. Cunningham, K.A., **De La Garza II, R.**, Callahan, P.M., Bodeker, D. Chronic fluvoxamine treatment: Electrophysiological and behavioral studies of cocaine. Paper presented at the annual meeting of ACNP, San Juan, Puerto Rico, December 1995.
12. **De La Garza II, R.**, Paredes, J.C., Perel, J.M. Comparative affinities of the serotonin transporter in platelets of depressed patients versus matched controls by selective binding of [<sup>3</sup>H]-citalopram. Paper presented at the annual meeting of ACNP, San Juan, Puerto Rico, December 1995.
13. Cunningham, K.A., Callahan, P.M., **De La Garza II, R.** Limbic circuitry and neurotransmitters involved in the discriminative stimulus properties of cocaine. Paper presented at the annual meeting of C.I.N.P., Colorado, January 1996.
14. Cunningham, K.A., **De La Garza II, R.**, Windh, R.T. The integrity of serotonin function and sensitization to cocaine. Paper presented at the annual meeting of the C.I.N.P., Colorado, January 1996.



15. Cunningham, K.A., **De La Garza II, R.**, Windh, R.T., Callahan, P.M. Serotonin (5-HT) 5-HT<sub>1A</sub> receptor function and the behavioral effects of cocaine. Paper presented at the annual meeting of the Texas Research Society on Alcoholism and Addiction, Austin, Texas, January 1996.
16. **De La Garza II, R.**, Cunningham, K.A. The 5-HT<sub>1A</sub> antagonist WAY 100635 attenuates cocaine-induced locomotor hyperactivity, but not behavioral sensitization. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 22: 931, 1996.
17. **De La Garza II, R.**, Madras, B.K. Autoradiographic localization of the dopamine transporter as measured by the novel radioligand [<sup>3</sup>H]-O-1059, a nonamine. Paper presented at the ASPET Summer Research Conference, Copper Mountain, CO, August 1997.
18. **De La Garza II, R.**, Madras, B.K. Autoradiographic distribution of dopamine D<sub>4</sub> receptors in non-human primate brain. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 23: 1137, 1997.
19. **De La Garza II, R.**, Meltzer, P.C., Madras, B.K. The distribution of a "nonamine" to dopamine-rich regions of monkey brain is similar to that of the monoamine. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 24: 278, 1998.
20. **De La Garza II, R.**, Madras, B.K. The D<sub>4</sub> dopamine receptor, labeled by [<sup>3</sup>H]U-101,958, distributes in nonhuman primate brain similar to that observed in human brain tissue: Dense localization in prefrontal cortex and hippocampus. Paper presented at the annual meeting of ACNP, Las Croabas, Puerto Rico, December 1998.
21. **De La Garza II, R.**, Madras, B.K. D<sub>4</sub> dopamine receptors, labeled by [<sup>3</sup>H]U-101,958, are dense in prefrontal cortex and hippocampus: implications for "novelty-seeking" behaviors and psychostimulant actions. Paper presented at the annual meeting of CPDD, Acapulco, Mexico, June 1999.
22. **De La Garza II, R.**, Miller, G.M., Yang, H., Novak, M.K., Madras, B.K. D<sub>4</sub> dopamine receptors in primate brain. Paper presented at the annual meeting of SfN. Soc. Neurosci. Abstr. 25: 2137, 1999.
23. Miller, G.M., **De La Garza II, R.**, Goulet, M., Yatin, S.M., Madras, B.K. Cloning of variants of the dopamine transporter, a principle target of cocaine, from three species of monkey brain. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2000, Drug Alcohol Depend. 60: S152.
24. **De La Garza, II, R.**, Verrico, C.D., Jentsch, J.D., Roth, R.H. Chronic fluoxetine and imipramine modulate PCP-induced monoamine turnover in brain. Paper presented at the annual meeting of SfN, New Orleans, LA, November 2000.
25. Miller, G.M., **De La Garza, II, R.**, Novak, M.K., Madras, B.K. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles: Implications for association with ADHD and other neuropsychiatric disorders. Paper presented at the annual meeting of SfN, New Orleans, LA, November 2000.
26. Taylor, J.R., Olausson, J.P., **De La Garza, II, R.**, Nestler, E.J., Jentsch, J.D. Withdrawal from repeated administration of cocaine produces impairments of reversal learning in monkeys. Paper presented at the annual meeting of SfN, New Orleans, LA, November 2000.
27. **De La Garza, II, R.**, Liu, X. 5-HT<sub>1A</sub> receptor mediation of hyperglycemia in an animal model of depression. Paper presented at the annual meeting of ASPET, Orlando, FL 2001.
28. **De La Garza, II, R.**, Liu, X. Wistar-Kyoto rats exhibit reduced intravenous nicotine self-administration behavior: Implications for an animal model of depression. Paper presented at the annual meeting of CPDD, Drug Alcohol Depend. (2002) 66 (Suppl 1) S42.
29. Asnis, G.M., Paladagu, R., Liu, X., **De La Garza, II, R.** The ability of specific NSAIDs to attenuate brain monoamine responses to  $\alpha$ -interferon exposure: distinct profiles in males versus females. Paper presented at the Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), sponsored by NIMH, 2002.
30. **De La Garza, II, R.**, Paladagu, R., Liu, X., Asnis, G.M. Role for NSAIDs on interferon-induced 5-HT changes: Useful for depression? Paper presented at the annual meeting of the American Psychiatric Association, Philadelphia, PA, May 2002.
31. Overstreet, D.H., File, S.E., Commissaris, R.C., **De La Garza, II, R.** Selective breeding for increased 5-HT<sub>1A</sub> receptor function: An animal model of co-morbid depression and anxiety. Paper presented at the annual meeting on Stress, IRELAND 2003.
32. **De La Garza, II, R.**, Fabrizio, K.R., Vlad, T., Asnis, G.M. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysachharide-induced depressive-like behavior. Paper presented at the annual meeting of ASPET, April 2003 (FASEB J. 17: A1024).
33. **De La Garza, II, R.**, McCaskie, A.M., Wittlin, A., Asnis, G.M. Animal models of interferon-induced depression: a role for NSAIDs. Paper presented at the annual meeting of the American Psychiatric Association, San Francisco,

CA, May 2003.

34. **De La Garza, II, R.**, Gupta, A., Jentsch, J.D. Altered corticolimbic dopamine and serotonin turnover following repeated treatment with ( $\pm$ ) 3,4-MDMA (“Ecstasy”). Paper presented at the annual meeting of CPDD, Bal Harbour, FL, June 2003.
35. **De La Garza, II, R.**, Asnis, G.M. NSAIDs for the treatment of IFN-alpha-induced depression in hepatitis C patients: Pre-clinical findings with diclofenac sodium. Paper presented at the annual meeting of CPDD, Bal Harbour, FL, June 2003.
36. **De La Garza, II, R.**, Stearns, C., Migdal, A.L., Pedrosa, E., Soltren, A., Asnis, G.M. Acute interferon-alpha does not alter reward behavior, neuroimmune or neuroendocrine activation, or monoamine turnover in rats. Paper presented at the annual meeting of ASPET, Washington, DC, April 2004.
37. **De La Garza, II, R.**, Fabrizio, K.R., Pedrosa, E., Asnis, G.M. Acute NSAID treatment attenuates lipopolysaccharide-induced alterations to reward behavior, monoamine turnover, and HPA axis activation. Paper presented at the annual meeting of ASPET, Washington, DC, April 2004.
38. **De La Garza, II, R.**, Stearns, C., Migdal, A.L., Pedrosa, E., Soltren, A., Asnis, G.M. The effects of chronic interferon-alpha on basic reward behavior, neuroimmune and neuroendocrine activation, and monoamine turnover in rats. Paper presented at the annual meeting of Biological Psychiatry, Biol. Psychiatry 55 (8), Supplement 1, 112s.
39. **De La Garza, II, R.**, Pedrosa, E., Stearns, C., Asnis, G.M. Chronic lipopolysaccharide results in tolerance to alterations to basic reward behavior, body weight, and food and water consumption. Paper presented at the annual meeting of Biological Psychiatry, Biol. Psychiatry 55 (8), Supplement 1, 59s.
40. Mahoney, III, J.J., Pedrosa, E., **De La Garza, II, R.** A distinct neurochemical profile for WKY rats at baseline and in response to acute stress: Implications for altered reward in animal models of anxiety and depression. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2004.
41. **De La Garza, II, R.**, Pedrosa, E., Granmayeh, L.K., Moeller, F.G., Silverman, P.B. MDMA (“ecstasy”) exposure results in impulsivity and is accompanied by long-term increases in 5-HT<sub>2A</sub> receptor mRNA in frontal cortex of rats. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2004.
42. **De La Garza, II, R.**, Newton, T.F., Elkashef, A., Smith, P. Physiological and subjective effects of methamphetamine in the presence of selegiline in human methamphetamine-addicted patients. Paper presented at the annual meeting of SfN, San Diego, CA, October 2004.
43. Cutting, D., Newton, T.F., Kalechstein, A.D., **De La Garza, II, R.** Low apathy is associated with increased craving for cocaine. Paper presented at the annual meeting of SfN, San Diego, CA, October 2004.
44. J.R. Ciullo, K.T. Wakabayashi, **R. De La Garza II**, D.B. Miller, W.E. Fantegrossi, J.H. Woods, Neurochemical effects of behaviorally and physiologically equivalent doses of methamphetamine and 3,4 - methylenedioxymethamphetamine in the mouse. Paper presented at the annual meeting of SfN, San Diego, CA, October 2004.
45. Wallace, CL, Newton, TF, Elkashef, A., Kahn, R., Mojsiak, J., **De La Garza, R.**, Chang, N., Roache, J.D. A phase I clinical safety study of the 3-way drug interactions between disulfiram, cocaine and alcohol in cocaine-dependent research volunteers. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
46. **De La Garza, II, R.**, Kalechstein, A.D., Nestor, L., Newton, T.F. A dissociation of the subjective and cardiovascular effects produced by cocaine or methamphetamine in stimulant-addicted patients. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
47. Mahoney, III, J.J., Kalechstein, A.D., **De La Garza, II, R.**, Newton, T.F. A meta-analytic review of cocaine-induced craving. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
48. Newton, T.F., Kalechstein, A.D., **De La Garza, R.**, Cutting, D.J., Ling, W. Apathy as a predictor of cocaine-induced craving. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
49. Jackson, B., **De La Garza, II, R.**, Newton, T.F. An examination of sleep alterations in methamphetamine-addicted patients. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
50. Fong, T., Newton, T.F., Roache, J.D., Kalechstein, A.D., **De La Garza, II, R.**, Wallace, C., Dawes, M., Bloch, D., Holmes, T., Elkashef, A., Chiang, N. The subjective effects of intravenous methamphetamine during treatment with bupropion. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
51. Kalechstein, A.D., Newton, T.F., **De La Garza, II, R.** Acute methamphetamine exposure worsens neurocognitive functioning. Paper presented at the annual meeting of CPDD, Orlando, FL, June 2005.
52. **De La Garza, II, R.**, Boss-Edwards, V., Hurley, C.L., Newton, T.F. The effects of stress imagery on the subjective

- measures of craving and mood in methamphetamine-addicted subjects. Paper presented at the American Psychological Association, Washington, DC, August 2005.
53. Mahoney, J.J., Kalechstein, A.D., **De La Garza, II, R.**, Newton, T.F. An analysis of the incidence, prevalence and persistence of psychotic behaviors in cocaine users as compared to methamphetamine users. Paper presented at the annual meeting of SfN, Orlando, FL, October 2005.
  54. Newton, T.F., Reid, M.S., **De La Garza, II, R.**, Palamar, J., Mahoney, J.J., Fong, T., Elkashef, A., Mojsiak, J., Chiang, N., Anderson, A., Jackson, B.J. A double-blind, placebo-controlled assessment of potential interactions between intravenous methamphetamine and aripiprazole. Paper presented at the annual meeting of SfN, Orlando, FL, October 2005.
  55. Evans, S.E., **De La Garza, II, R.**, Newton, T.F. An evaluation of the impact of lifetime or current smoking patterns on the acute subjective effects produced by methamphetamine in the laboratory. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  56. Mahoney, III, J.J., **De La Garza, II, R.**, Culbertson, C., Fintzy, R., Newton, T.F. Effects of rivastigmine treatment on intravenous self-administration of methamphetamine in methamphetamine-dependent volunteers. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  57. Newton, T.F., **De La Garza, II, R.**, Kalechstein, A.D. Methamphetamine- or cocaine-induced craving: cause or consequence of frequent drug use? Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  58. Jackson, B.J., Kalechstein, A.D., **De La Garza, II, R.**, Harrison, L., Franco, Z., Newton, T.F. An evaluation of the effects of rivastigmine on neurocognition in methamphetamine-dependent volunteers. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  59. O'Laco, E., **De La Garza, II, R.**, Mahoney, III, J.J., Shoptaw, S., Newton, T.F. A double-blind, placebo-controlled assessment of potential interactions between intravenous methamphetamine and rivastigmine: cardiovascular and subjective effects. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  60. Harrison, L., **De La Garza, II, R.**, Hurley, C., Evans, S.E., Fleury, G., Boss-Edwards, V., Newton, T.F. The effects of stress imagery on the subjective measures of craving and mood in methamphetamine-addicted volunteers. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  61. Kalechstein, A.D., **De La Garza, II, R.**, Newton, T.F. Effects of Bupropion SR on neurocognition in volunteers with methamphetamine dependence. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  62. **De La Garza, II, R.**, Newton, T.F. Individual variability in addiction profiles: Importance for medications development. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  63. Fox, R.G., Herin, D., **De La Garza, II, R.**, Newton, T.F., Napier, T.C., Cunningham, K.A. The effects of Disulfiram on methamphetamine-induced conditioned place preference. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  64. Reid, M.S., Palamar, J., Flammiano, F., Mahoney, J.J., **De La Garza, R.**, Newton, T., Elkashef, A., Mojsiak, J., Chiang, N., Anderson, A. A double-blind, placebo-controlled assessment of aripiprazole effects on methamphetamine craving: longitudinal and cue reactivity studies. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2006.
  65. **R. De La Garza, II**, G. Fleury, E.M. Wagreich, J. McCracken, T.F. Newton. Is the DAT 9/9 genotype protective against the development of methamphetamine dependence? Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  66. P.B. Yang, **R. De La Garza, II**, T. F. Newton. Increased heart rate and motor activity with illicit methamphetamine use in a naturalistic setting compared to controlled settings. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  67. A.D. Kalechstein, B. Jackson, **R. De La Garza, II**, T.F. Newton. Acute administration of methamphetamine does not alter cognitive function in abstinent methamphetamine-dependent individuals. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  68. G. Fleury, J.J. Mahoney, III, **R. De La Garza, II**, T.F. Newton. Determinants of cardiovascular response to methamphetamine. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  69. C.S. Culbertson, M.R. Costello, C.A. Kenny, D. Tziortzis, E. O'Laco, **R. De La Garza, II**, T.F. Newton. Gender differences in motivation to abstain from methamphetamine use. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  70. T.F. Newton, **R. De La Garza, II**, K. Grasing, R. Donovan, Z. Franco. Perindopril attenuates methamphetamine-induced subjective effects, implicating angiotensin II in mediating effects of stimulants. Paper presented at the

- annual meeting of CPDD, Quebec City, CANADA, June 2007.
71. J.J. Mahoney, III, P. Yurovsky, A.R. Dillon, A.D. Kalechstein, **R. De La Garza, II**, T.F. Newton. An analysis of the prevalence and persistence of psychotic behaviors in cocaine- vs. methamphetamine-dependent participants. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  72. B. Jackson, **R. De La Garza II**, T.F. Newton. Sleep disturbances and excessive daytime sleepiness in methamphetamine-dependent individuals: implications for cognitive function. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  73. L.G. Harrison, **R. De La Garza, II**, V. Boss-Edwards, M.R. Costello, T.F. Newton. Stress imagery exposure in cocaine-dependent participants elicits subtle increases in desire and anxiety. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  74. C.A. Kenny, S. E. Evans, **R. De La Garza, II**, K. Gunnia, A.D. Kalechstein, T.F. Newton. Self-perceived Explanations for Drug Use and Relapse among Methamphetamine-addicted Volunteers. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  75. M.R. Costello, **R. De La Garza II**, C. Hurley, R.E. Fintzy, A.D. Kalechstein, T.F. Newton. Unrestricted access to methamphetamine in the past is associated with increased use of methamphetamine in the present. Paper presented at the annual meeting of CPDD, Quebec City, CANADA, June 2007.
  76. T.F. Newton, **R. De La Garza, II**, A.D. Kalechstein, R.A. Donovan, C. Kenny. Theories of addiction: Assessment of methamphetamine-dependent participants' explanations of their own drug use. Paper presented at the annual meeting of SfN, San Diego, CA, November 2007.
  77. T.F. Newton, **R. De La Garza, II**, A. Lee, R.A. Donovan, K.G. Heinzerling, S. Shoptaw. The effects of  $\gamma$ -vinyl- $\gamma$ -aminobutyric acid (GVG, vigabatrin) on the subjective, cardiovascular and reinforcing effects produced by methamphetamine (METH) in METH-dependent volunteers. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2008.
  78. **R. De La Garza, II**, T.F. Newton, T.S. Zorick, E.D. London. Modafinil attenuates subjective effects of methamphetamine in methamphetamine-dependent research subjects. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2008.
  79. C. Culbertson, I. Zaharovits, **R. De La Garza, II**, T.F. Newton. Developing and testing of a novel virtual reality device in methamphetamine-dependent humans. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2008.
  80. B.J. Jackson, A.D. Kalechstein, **R. De La Garza, II**, T.F. Newton. Acute modafinil treatment does not improve cognitive function in methamphetamine-dependent volunteers. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2008.
  81. J. Zhuo, K. Whittaker, **R. De La Garza, II**, T.F. Newton, G.C. Baldwin. Methamphetamine-related immune system changes in methamphetamine-dependent participants. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2008.
  82. **R. De La Garza, II**, T.F. Newton, M. Lokireddy, C.N. Haile, R. Hawkins, S. Mehtani, G. Brown, Y. Omar, J.J. Mahoney, III. Impact of treatment with the acetylcholinesterase inhibitor rivastigmine on methamphetamine-induced subjective and reinforcing effects. Paper presented at the annual meeting of the Rush and Helen Record Neuroscience Forum, Galveston, TX, February 2010.
  83. J.H. Yoon, C. Culbertson, R. Fintzy, C.N. Haile, R.Y. Hawkins, J.J. Mahoney, H.R. Patel, T.F. Newton, **R. De La Garza, II**. Cognitive behavioral therapy, nicotine cue-exposure, and D-cycloserine for treating cigarette smoking among those with cocaine dependence. Paper presented at the annual meeting of Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD, February 2010.
  84. Roache J, Newton T, **De La Garza, R**, Murff W, Wallace C. Safety of disulfiram in cocaine addicts who drink. Paper presented at the annual meeting of Texas Research Society on Alcoholism and Addiction, Houston, TX, February 2010.
  85. D. Tziortzis, J.J. Mahoney, III, A.D. Kalechstein, T.F. Newton, **R. De La Garza, II**. Impulsivity + craving = drug use? Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2010.
  86. S. Raju, **R. De La Garza, II**. Concurrent nicotine and methamphetamine dependence - why use both? Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2010.
  87. R. Hawkins, J. J. Mahoney, III, A.D. Kalechstein, **R. De La Garza, II**, T.F. Newton. The relationship between gender and psychotic symptoms in cocaine- and methamphetamine-dependent volunteers. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2010.

88. J. Yoon, C. Culbertson, R. Fintzy, C. Haile, R. Hawkins, J. Mahoney, K. Labounty, D. Croft, H. Patel, T. Newton, **R. De La Garza, II**. Effects of D-cycloserine on extinction of nicotine cues among cocaine-dependent cigarette smokers. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2010.
89. **R. De La Garza, II**, T.F. Newton, M. Lokireddy, C.N. Haile, R. Hawkins, S. Mehtani, G. Brown, Y. Omar, J.J. Mahoney, III. Impact of rivastigmine treatment on methamphetamine-induced subjective and reinforcing effects. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2010.
90. C.N. Haile, **R. De La Garza II**, J.J. Mahoney, III, A.D. Kalechstein, T.F. Newton. Theories of addiction: cocaine users' explanation for continuing drug use and relapse. Paper presented at the annual meeting of CPDD, Scottsdale, AZ, June 2010.
91. K. McCurry, G. Brown, **R. De La Garza**, T. Newton, P. Chiu, B. King-Casas. Neural correlates of aggression in cocaine dependent individuals. Paper presented at the annual meeting of SfN. San Diego, November 2010.
92. L. Lindsey, K. McCurry, H. Patel, S. LaConte, **R. De La Garza**, T. Newton, B. King-Casas, P. Chiu. Neural substrates of drug use, craving, and executive control in cocaine users. Paper presented at the annual meeting of SfN, San Diego, November 2010.
93. J. Lu, G. Christopoulos, K. McCurry, Y. Omar, **R. De La Garza**, T. Newton, B. King-Casas, P. Chiu. Neural substrates of social influence on risk preferences in cocaine users. Paper presented at the annual meeting of SfN, San Diego, November 2010.
94. D. Tankersley, K. McCurry, G. Christopoulos, T. Newton, **R. De La Garza**, B. King-Casas, P. Chiu. Reward and punishment learning associated with differential response to positive and negative prediction errors in stimulant-dependent subjects. Paper presented at the annual meeting of SfN, San Diego, November 2010.
95. H. Singh, M.R. Lokireddy, J.J. Mahoney, III, T.F. Newton, **R. De La Garza II**. The impact of marijuana use on high and desire for cocaine in cocaine-dependent individuals. Paper presented at the annual meeting of the American Academy of Addiction Psychiatry, San Diego, CA, December 2010.
96. T.F. Newton, **R. De La Garza, II**, C.N. Haile, T.R. Kosten. The noradrenergic  $\alpha 1$  receptor antagonist doxazosin attenuates the subjective effects of cocaine in non-treatment-seeking, cocaine-dependent volunteers. Paper presented at the annual meeting of ACNP, Miami, FL, December 2010.
97. **R. De La Garza, II**, T.F. Newton, C.S. Nerumalla, C.N. Haile, J.J. Mahoney, A. Aziziyeh. The acetylcholinesterase inhibitor rivastigmine reduces methamphetamine-induced "desire" and "likely to use" in methamphetamine-dependent volunteers. Paper presented at the annual meeting of ACNP, Miami, FL, December 2010.
98. C.S. Nerumalla, E.L. Ross, J.J. Mahoney, III, T.F. Newton, **R. De La Garza, II**. Does nicotine use alter the "high" or "desire" for cocaine among cocaine-dependent smokers? Paper presented at the annual meeting of SRNT, Toronto, Ontario, Canada, February 2011.
99. J.H. Yoon, A.D. Kalechstein, D.E. Croft, E.L. Ross, K.R. LaBounty, J.J. Mahoney, III, T.F. Newton, **R. De La Garza, II**. Effects of D-cycloserine on neurocognition among cocaine-dependent volunteers being treated for cigarette smoking. Paper presented at the annual meeting of SRNT. Toronto, Ontario, Canada, February 2011.
100. **R. De La Garza, II**, T.F. Newton, C.N. Haile, S.Mehtani, R.Y. Hawkins, J.J. Mahoney. Escitalopram attenuates modafinil's therapeutic action in cocaine-dependent volunteers. Paper presented at the annual meeting of CPDD, Hollywood, FL, June 2011.
101. T.F. Newton, **R. De La Garza, II**, T.R. Kosten, C.N. Haile. The noradrenergic  $\alpha 1$  receptor antagonist doxazosin attenuates craving produced by cocaine in non-treatment-seeking, cocaine-dependent volunteers. Paper presented at the annual meeting of CPDD, Hollywood, FL, June 2011.
102. J.J. Mahoney, III, A. Aziziyeh, S. Harrison, T.F. Newton, **R. De La Garza, II**. Lifetime stress is associated with greater increased daily use of cocaine and nicotine, and elevated ASI and BDI scores, in cocaine-dependent participants Paper presented at the annual meeting of CPDD, Hollywood, FL, June 2011.
103. J.H. Yoon, C.S. Nerumalla, Y. Omar, G.S. Brown, **R. De La Garza, II**, T.F. Newton. Inter-temporal choice among methamphetamine-dependent volunteers: comparison of immediately available money versus methamphetamine. Paper presented at the annual meeting of CPDD, Hollywood, FL, June 2011.
104. T. Newton, C.N. Haile, **R. De La Garza, II**, T.R. Kosten, J. Mahoney. Dose-dependent effects of disulfiram on choice of cocaine over a monetary alternative. Paper presented at the annual meeting of the Society for Neuroscience, Washington, DC, November 2011.
105. J.H. Yoon, N.M. Arnoudse, S.P. Apodaca, **R. De La Garza, II**. Remote physiological monitoring of cigarette smoking. Paper presented at the 9th Annual Duncan Cancer Center Symposium, Houston, TX, Nov 2011.

106. C.N. Haile, **R. De La Garza, II**, J. Mahoney, T.R. Kosten, T.F. Newton. Dose-dependent effects of disulfiram on choices for cocaine over a monetary alternative in cocaine-dependent volunteers. Paper presented at the annual meeting of the Winter Conference on Brain Research (WCBR), Snow Bird, Utah, February 2012.
107. J.H. Yoon, R.S. Shah, K.N. Cooper, A.J. Brewer, III, **R. De La Garza, II**. Modafinil does not alter cigarette use or cravings in cocaine-dependent volunteers. Paper presented at the annual meeting of SRNT, Houston, TX, March 2012.
108. J.H. Yoon, N.M. Arnoudse, S.P. Apodaca, R.S. Shah, **R. De La Garza, II**. Remote physiological monitoring of cigarette smoking. Paper to be presented at the annual meeting of SRNT, Houston, TX, March 2012.
109. A.J. Brewer, III, S.F. Loar, K.N. Cooper, T.F. Newton, **R. De La Garza, II**. Evaluation of the impact of cigarette smoking on the “high” and “desire” produced by methamphetamine (METH) among METH-dependent volunteers. Paper presented at the annual meeting of SRNT, Houston, TX, March 2012.
110. M.B. Hinojosa, C.S. Nerumalla, J. Mahoney, III, T. Newton, **R. De La Garza, II**. Lack of gender differences in nicotine use among non-treatment seeking methamphetamine and cocaine users. Paper presented at the annual meeting of SRNT, Houston, TX, March 2012.
111. Yoon, J.H., Arnoudse, N.M., Shah, R.S., Apodaca, S.P., **De La Garza, II, R.** Characterizing a profile of acute cocaine exposure in the laboratory using remote physiological monitoring. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
112. Verrico, C.D., Newton, T.F., Meyer, S.A., **De La Garza, II, R.** The impact of marijuana use on high and desire for cocaine in cocaine-dependent individuals. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
113. Mahoney, III, J.J., Omar, Y., Cooper, K., Ross, E., **De La Garza, II, R.**, Newton, T.F. Lifetime stress is associated with elevated addiction severity index scores in methamphetamine-dependent participants. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
114. Hinojosa, M., **De La Garza, II, R.**, Mahoney, III, J.J., Ho, A., Newton, T.F. Gender differences in response to bupropion in methamphetamine users. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
115. Kalechstein, A., Mahoney, III, J.J., Hinojosa, M., Bennett, R., Shah, R., Croft, D., Newton, T.F., **De La Garza, II, R.** Gender does not influence neurocognitive performance in methamphetamine- and cocaine-dependent participants. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
116. Newton, T.F., **De La Garza, II, R.**, Mahoney, III, J.J., Omar, Y., Haile, C., Shorter, D., Hawkins, R., Nerumalla, C. The ACE inhibitor perindopril may attenuate psychostimulant effects produced by methamphetamine in non-treatment-seeking, methamphetamine-dependent volunteers. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
117. Beveridge, T., Brewer, A., Wray, P., Shapiro, B., Mahoney, III, J.J., Newton, T.F., **De La Garza, II, R.** Human cocaine use patterns – relevance to the development of animal models of addiction. Paper presented at the annual meeting of CPDD, Palm Springs, CA, June 2012.
118. Asnis, G.M., Majeed, K., Henderson, M., **De La Garza, R.** Tinnitus co-morbid with insomnia: a significant relationship and implications. Paper presented at the annual meeting of the International College of Neuro-Psychopharmacology, Stockholm SWEDEN, June 2012.
119. Mahoney, III, J.J., **De La Garza, II, R.**, Jackson, B.J., Dao, T.K., Bannister, J.A., Milliken, L, Newton. The relationship between self-reported sleep habits, daytime sleepiness, and drug use characteristics in cocaine and methamphetamine-dependent participants. Paper presented at the annual meeting of the American Psychological Association, Orlando, FL, August 2012.
120. Yoon, J.H., Fritz, J.F., Brown, M.R., Newton, T.F., **De La Garza, R., II**. Comparison of k and AUC with equal and unequal delays. Oral presentation for the annual meeting of the American Psychological Association, Orlando, FL. August 2012.
121. Newton, T.F., Haile, C.N., **De La Garza, II, R.**, Mahoney, III, J.J. Daily treatment with the dopamine 2/3 receptor agonist pramipexole enhances the cardiovascular and subjective effects of cocaine in cocaine-dependent volunteers. Paper presented at the annual meeting of SfN, New Orleans, LA, October 2012.
122. **De La Garza, II, R.**, Galloway, G.P., Newton, T.F., Mendelson, J., Haile, C.N., Dib, E., Hawkins, R.Y., Chen, C-Y A., Mahoney, III, J.J., Mojsiak, J., Lao, G., Anderson, A., Kahn, R. Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine. Paper presented at the annual meeting of ACNP, Hollywood, FL, December 2012.

123. Verrico, C.D., Mahoney, III, J.J., Bennett, R.S., Newton, T.F., **De La Garza, II, R.** Varenicline attenuates methamphetamine-induced subjective effects in methamphetamine-dependent volunteers. Paper to be presented at the annual meeting of ACNP, Hollywood, FL, December 2012.
124. Mahoney, J.J., III, Kalechstein, A.D., Newton, T.F., Bennett, R., Arnoudse, N., Dao, T.K., **De La Garza, II, R.** The acetylcholinesterase inhibitor, rivastigmine, but not huperzine a, improves verbal learning/episodic memory and working memory in cocaine-dependent volunteers. Paper presented at the annual meeting of ACNP, Hollywood, FL, December 2012.
125. Haile, C.N., Shorter, D., O'Malley, P., Lindsay, J.A., **De La Garza II, R.**, Kosten, T.A., Kosten, T.R., Newton, T.F. The  $\alpha 1$  antagonist doxazosin blocks cocaine-induced sensitization in rats and reduces the subjective and reinforcing effects of cocaine in cocaine-dependent individuals. Paper presented at the annual meeting of WCBR, Breckenridge, CO, January 2013.
126. Thekdi, S., Spelman, A., Wood, C., Tannir, N., Jonasch, E., Gardino, J., Pisters, L., Johnson, K., Wei, Q., Matin, S., **De La Garza, II, R.**, Cohen, L. Emotional Distress in Renal Cell Carcinoma: Who is at Risk and What Factors are Protective? Paper presented at the annual meeting of The American Psychosocial Society, Huntington Beach, CA, February 2013.
127. Mahoney, III, J.J., Kalechstein, A.D., Newton, T.F., Yoon, J.H., Bennett, R.S., Arnoudse, N., Meyer, S., **De La Garza, II, R.** Cigarette smoking does not affect neurocognition in cocaine- or methamphetamine-dependent individuals. Paper presented at the annual meeting of SRNT, Boston, MA, March 2013.
128. Yoon, J.H., Bennett, R.S., Arnoudse, N.M., **De La Garza, II, R.** Varenicline is well tolerated by methamphetamine-dependent cigarette smokers. Paper presented at the annual meeting of SRNT, Boston, MA, March 2013.
129. Brewer, A.J., III, Arnoudse, N., Mahoney, J.J., III, Newton, T.F., **De La Garza, II, R.** Subjective and Cardiovascular Responses to Cocaine Differ in Cigarette Smokers versus Nonsmokers. Paper presented at the annual meeting of ASPET, Boston, MA, April 2013.
130. Mahoney, J.J., III, Newton, T.F., Shapiro, B., **De La Garza, II, R.** A Comparison of the Subjective and Cardiovascular Effects Produced by Exposure to Intravenous versus Smoked Methamphetamine in the Laboratory. Paper presented at the annual meeting of ASPET, Boston, MA, April 2013.
131. Yoon, J.H., Arnoudse, N.M., Shah, R.S., Apodaca, S.P., **De La Garza, II, R.** Characterizing a profile of acute cocaine exposure in the laboratory using remote physiological monitoring. Oral presentation for the annual meeting of American Telemedicine Association Annual International Meeting & Trade Show, Austin, TX, May, 2013.
132. Haile, C.N., Murrough, J.J., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Foulkes, A., Iqbal, S., Mahoney, III, J.J., **De La Garza, II, R.**, Charney, D.S., Newton, T.F., Mathew, S.J. Ketamine for treatment-resistant depression: subjective effects and impact on plasma brain-derived neurotrophic factor. Paper presented at the annual meeting of CPDD, San Diego, CA, June 2013.
133. Brewer, A.J., Nielsen, D.A., Spellicy, C.J., Hamon, S.C., Gingrich, J., Mahoney, III, J.J., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** Subjective effects produced by cocaine are in association with genetic variants of DAT1. Paper presented at the annual meeting of CPDD, San Diego, California, June 2013.
134. Verrico, C.D., Nielsen, D.A., Spellicy, C.J., Hamon, S.C., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** Fatty acid amide hydrolase gene variant influences acute responses to cocaine. Paper presented at the annual meeting of CPDD, San Diego, California, June 2013.
135. Kalechstein, A.D., Mahoney, III, J.J., Verrico, C.D., Iqbal, T., Bennett, R., **De La Garza, II, R.** Short-term, low-dose varenicline administration improves aspects of information processing speed and verbal memory, but not working memory, in methamphetamine (METH)-dependent participants. Paper presented at the annual meeting of CPDD, San Diego, California, June 2013.
136. Thompson-Lake, D.G.Y., Yoon, J.H., Viswanath, H., Carter, A.Q., Bordnick, P.S., Salas, R., Kosten, T.R., Dani, J.A., **De La Garza, II, R.** Virtual reality-induced craving for cigarettes among abstinent smokers. Paper presented at the annual meeting of CPDD, San Diego, California, June 2013.
137. Mahoney, J.J., III, Kalechstein, A.D., Newton, T.F., Meyer, S., Bennett, R., Chang, L., **De La Garza, II, R.** State versus Trait: Evaluating the stability of neurocognitive functioning over time in cocaine-dependent participants. Paper presented at the annual meeting of CPDD, San Diego, California, June 2013.
138. Newton, T.F., Hawkins, R., Arnoudse, N., Jiang, X., Cooper, K., **De La Garza, II, R.**, Mahoney, III, J.J., Kosten, T.R., Doxazosin treatment for methamphetamine dependence. Paper presented at the annual meeting of

CPDD, San Diego, California, June 2013.

139. McDevitt, J.T., **De La Garza, II, R.**, Newton, T.F., Smith, R., Mahoney, III, J.J., Hohenstein, J., Gomez, S., Floriano, P.N., Talavera, H., Sloan, D.J., Moody, D.E., Andrenyak, D.M., Kosten, T.R., Christodoulides, N. Programmable bio-nano-chips for the quantitation of drugs of abuse in oral fluids. Paper presented at the annual meeting of CPDD, San Diego, California, June 2013.
140. Yoon, J.H., **De La Garza, II, R.**, Bordnick, P.S., Hawkins, R.Y., Shapiro, B.A., Croft, D.E., Levin, H.S. A pilot study examining the efficacy of virtual reality based relapse prevention among alcohol-dependent veterans with traumatic brain injury. Paper presented at the annual meeting of CPDD, San Diego, CA, June 2013.
141. Nielsen, D.A., Spellicy, C.J., Hamon, S.C., Harding, M.J., Mahoney, III, J.J., Kosten, T.R., **De La Garza, II, R.**, Newton, T.F. Genetic variants of the dopaminergic system associated with subjective responses to cocaine. Paper presented at the annual meeting of CPDD, San Diego, CA, June 2013.
142. Savjani, R.R., Cai, M., Thompson-Lake, D.G.Y., Cui, Y., Lisinski, J., **De La Garza, II, R.**, LaConte, S., Eagleman, D.M. Modulating craving states in cocaine addiction via real-time fMRI feedback. Paper presented at the annual meeting of SfN, San Diego, CA, November 2013.
143. Chung, D., Christopoulos, G., Newton, T.F., **De La Garza, II, R.**, King-Casas, B., Chiu, P. Cocaine addicts show increased susceptibility to social influence during risky decision making. Paper presented at the annual meeting of SfN, San Diego, CA, November 2013.
144. Nielsen, D.A., Spellicy, C.J., Hamon, S.C., Mahoney, III, J.J., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** Subjective responses to cocaine in association with genetic variants of the dopaminergic system. Paper presented at the annual meeting of SfN, San Diego, CA, November 2013.
145. Mahoney, III, J.J., Kalechstein, A.D., Verrico, C.D., Iqbal, T., Newton, T.F., **De La Garza, II, R.** The impact of cocaine use patterns, demographic and mood variables, and addiction severity on neurocognitive functioning in individuals with cocaine use disorders. Paper presented at the annual meeting of ACNP, Hollywood, FL, December 2013.
146. Verrico CD, Mahoney III JJ, Cooper KN, Iqbal T, Newton TF, **De La Garza, II R.** Safety and efficacy of short-term treatment with the acetylcholinesterase inhibitors rivastigmine and huperzine A to reduce the subjective and reinforcing effects produced by acute cocaine exposure. Paper presented at the annual meeting of ACNP, Hollywood, FL, December 2013.
147. Yoon, J.H., Newton, T.F., Hawkins, R.Y., **De La Garza, II, R.** Assessment of doxazosin XL as a treatment for nicotine dependence. Paper presented at the annual meeting of SRNT, Seattle, WA, February 2014.
148. Thompson-Lake, D.G.Y., Yoon, J. H., Cooper, K., Bordnick, P.S., Salas, R., Kosten, T.R., Dani, J.A., **De La Garza, II, R.** Effects of acute nicotine deprivation on craving, withdrawal, and virtual-reality-based cue reactivity. Paper presented at the annual meeting of SRNT, Seattle, WA, February 2014.
149. Kalechstein, A.D., Mahoney, III, J.J., Verrico, C.D., Iqbal, T., **De La Garza, II, R.** Varenicline improves information processing speed and verbal memory in methamphetamine (METH)-dependent participants. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June, 2014.
150. Wesley, M.J., Lohrenz, T., Koffarnus, M.N., McClure, S.M., **De La Garza, II, R.**, Newton, T.F., Bickel, W.K., Montague, P.R. Choosing money over drugs: the underpinnings of rational choice in cocaine addicts. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June, 2014.
151. Verrico, C.D., Thompson-Lake, D., Iqbal, T., Mahoney, III, J.J., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** Evaluation of guanfacine administration on cognition in volunteers with cannabis-use disorder. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June, 2014.
152. Thompson-Lake, D.G.Y., Cooper, K., Mahoney, III, J.J., Gatchalian, K., Koffarnus, M., Salas, R., Lohrenz, T., Bickel, W., Montague, P.R., Newton, T.F., **De La Garza, II, R.** Comparison of perceptions of HIV risk and risky sexual practices among heterosexual cocaine-dependent individuals. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2014.
153. Haile, C.N., Thompson-Lake, D.G., Mahoney, III, J.J., Newton, T.F., **De La Garza, II, R.** Cocaine-induced subjective effects differ between African Americans and Caucasians. Paper presented at the annual meeting of CPDD, San Juan, Puerto Rico, June 2014.
154. Wang, J.M., Zhu, L., **De La Garza, II, R.**, Newton, T.F., McCurry, K., King-Casas, B., Chiu, P.H. Cocaine use modulates neurobehavioral substrates of loss aversion in a probabilistic learning task. Paper presented at the annual meeting of The Organization of Human Brain Mapping, Hamburg, Germany June 2014.
155. Rashid, A., Torres, H., Jorewicz, L., **De La Garza, II, R.** Incidence and characteristics of depression in



- cancer patients with chronic hepatitis c infection. Paper presented at the annual meeting of the International Psycho-Oncology Society, Lisbon, Portugal, June 2014.
156. Rashid, A., **De La Garza, II, R.** Integrative approach counseling in the outpatient psychiatry clinic. Paper presented at the annual meeting of The American Society of Clinical Oncology, Chicago, IL, October 2014.
  157. **De La Garza, II, R.**, Thompson-Lake, D.G.Y., Haile, C.N., Eisenhofer, J.D., Newton, T.F., Yoon, J.H., Mahoney, III, J.J. Treadmill exercise improves fitness and reduces craving and use of cocaine in individuals with cocaine and tobacco-use disorder. Paper presented at the annual meeting of ACNP, Phoenix, AZ, December 2014.
  158. Shorter, D.I., Nielsen, D.A., Hamon, S., Nielsen, E., Kosten, T.R., Newton, T.F., **De La Garza, II, R.** Alpha-1 adrenergic receptor (ADRA1A) genotype influences magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Paper presented at the annual meeting of ACNP, Phoenix, AZ, December 2014.
  159. Rodgman, C., Haile, C.N., Hawkins, R., Thompson-Lake, D.G.Y., Mahoney, J.J., **De La Garza, II, R.**, Newton, T.F. Novel antiepileptic carisbamate alters the subjective effects of alcohol in human subjects. Paper presented at the annual meeting of ACNP, Phoenix, AZ, December 2014.
  160. **De La Garza, II, R.**, Eisenhofer, J.D., Thompson-Lake, D.G.Y., DeBrule, D.S., Makanjuola, T., Rodgman, C., Newton, T.F., Yoon, J.H. A preliminary study of the effects of an exercise regimen on craving and use of cigarettes in individuals with concurrent cocaine- and tobacco-use disorder. Paper presented at the annual meeting of SRNT, Philadelphia, PA, February 2015.
  161. Savjani, R.R., Cai, M., Niakan, L., Thompson, D.G., **De La Garza, R.**, Eagleman, D.M. Modulating Craving States in Cocaine Addiction via Real-time fMRI Feedback. Paper presented at the Real-time Functional Imaging and Neurofeedback conference, Gainesville, FL, February 2015.
  162. Thompson-Lake, D.G.Y., Hernandez, S., Holst, M., Mahoney, III, J.J., Haile, C.N., Newton, T.F., **De La Garza, II, R.** An in-depth analysis of cocaine-induced negative subjective effects in humans. Paper to be presented at the annual meeting of CPDD, Phoenix, AZ, June 2015.
  163. Eisenhofer, J.D., Makanjuola, T., Martinez, V.M., Thompson-Lake, D.G.Y., Rodgman, C., DeBrule, D.S., Graham, D.P., **De La Garza, II, R.** Efficacy of electronic cigarettes (E-cigs) for smoking cessation in veterans. Paper to be presented at the annual meeting of CPDD, Phoenix, AZ, June 2015.
  164. **De La Garza, II, R.**, Thekdi, S., Rashid, A., Lynn, R., Ignatius, J., Gonzalez, R., Tan, D., Rickman, K., Hughes, M., Joseph, N., Onyemeh Sea, A., Smith, C., Bell, M., Valentine, A. Characterization of Demographics and Psychiatric Symptoms in 500 Patients Enrolled in the M.D. Anderson Cancer Center Psychiatry Patient Registry Protocol. Paper to be presented at the annual meeting of the World Congress of Psycho-Oncology, July 2015.
  165. Ignatius, J., Bell, M., Rashid, A., Thekdi, S., **De La Garza, R.**, Nichols, D., Valentine, A. PsychCare Database: Development and Implementation. Paper to be presented at the annual meeting of the World Congress of Psycho-Oncology, July 2015.
  166. Rashid, A., **De La Garza, II, R.**, Joseph, N., Onyemeh Sea, A., Valentine, A. Correlations of High Edmonton Symptom Assessment Scale Scores to Demographic and Other Variables. Paper to be presented at the annual meeting of the World Congress of Psycho-Oncology, July 2015.
  167. Lynn, R., **De La Garza, II, R.**, Joseph, N., Onyemeh Sea, A., Valentine, A. Use of the NCCN Distress Thermometer and Emotional Problem List in Predicting Psychiatric Symptoms. Paper to be presented at the annual meeting of the World Congress of Psycho-Oncology, July 2015.

#### NCBI GenBank Published Nucleotide Sequences:

1. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF287464, *Saimiri sciureus* dopamine transporter gene allele A, 3'untranslated region, 884 bp DNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF287464>
2. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF287463, *Macaca mulatta* dopamine transporter gene allele B, 3' untranslated region, 883 bp DNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF287463>
3. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF287462, *Macaca mulatta* dopamine transporter gene allele A, 3' untranslated region, 884 bp DNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF287462>
4. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF286450, *Saimiri sciureus* dopamine transporter variant II mRNA, complete cds, 2062 bp mRNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF286450>
5. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF286449, *Saimiri sciureus* dopamine transporter variant I mRNA, complete cds, 2062 bp mRNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF286449>

6. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF286448, *Macaca fascicularis* dopamine transporter variant I mRNA, complete cds, 2062 bp mRNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF286448>
7. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF286447, *Macaca fascicularis* dopamine transporter mRNA, complete cds, 2062 bp mRNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF286447>
8. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF286446, *Macaca mulatta* dopamine transporter variant II mRNA, complete cds, 2062 bp mRNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF286446>
9. Miller, G.M., **De La Garza, R. II** and Madras, B.K., AF286445, *Macaca mulatta* dopamine transporter mRNA, complete cds, 2062 bp mRNA, August 2000. <http://www.ncbi.nlm.nih.gov/nuccore/AF286445>

### Teaching Information:

#### Lectures Given at BCM, MEDVAMC, and MDACC

1. "Neurobiology of Addiction". Invited lecture for BCM PGY2 Psychiatry residents, February 5, 2009.
2. "Novel Medications for Cocaine- and Methamphetamine-Addiction". Invited lecture BCM Menninger Department of Psychiatry, Division on Addictions, February 26, 2009.
3. "Neurobiology of Nicotine Addiction". Invited lecture for BCM PGY1 Psychiatry residents, March 24, 2009.
4. "Medications Testing for Stimulant Addiction: Acetylcholine as a Neurotransmitter System of Interest". Invited lecture, BCM Neuroscience Department, April 16, 2009.
5. "Clinical Research for Cocaine and Methamphetamine Addiction". Invited lecture, DeBakey High School Scientific Symposium, December 18, 2009.
6. "Brain and Behavior Addiction". Invited lecture for BCM PGY2 Psychiatry residents, February 4, 2010.
7. "Translational Neuroscience of Addiction". Invited lecture for BCM Bench to Bedside course, Translational Biology and Molecular Medicine Graduate Program, April 8, 2011.
8. "Preparing for and Conducting Clinical Research". Invited Grand Rounds lecture, Department of Anesthesiology, March 16, 2011.
9. "The Use of Virtual Reality in the Treatment of PTSD and Co-Occurring Addictive Diseases". Invited lecture for PTSD conference for MEDVAMC, May 25, 2011.
10. "Conducting Phase 1 Clinical Trials for Drug Addiction". Invited lecture for the BCM Office of Diversity Summer Research Program for Houston area high school students, Houston, TX, July 21, 2011.
11. "A Brief Overview of Nicotine, Alcohol and Cocaine Research at the MEDVAMC". Invited Presentation for the MEDVAMC Medical Center Director's Management Advisory Council, September 22, 2011.
12. "Mechanisms of Addiction: Neurophysiological & Behavioral correlates". Invited lecture for MDACC Bio-Behavioral Research Methods course, January 27, 2012.
13. "Addiction: Human Laboratory Research Guiding Treatment Discovery". Invited lecture for MDACC Bio-Behavioral Research Methods course, March 2, 2012.
14. "Brain Development Trajectories and Susceptibility to Addiction". Invited lecture for BCM Human Development course for BCM 1st year medical students, March 27, 2012.
15. "Breaking Addiction's Death Grip Through Memory Disruption". Invited presentation for the MEDVAMC VA National Research Week Event titled *Caring for Veterans through Discovery & Collaboration*, April 27, 2012.
16. "Update on Research Within the Division of Addictions". Invited presentation for the BCM Department of Psychiatry Quarterly Faculty Meeting, May 30, 2012.
17. "Drugs for Affective Disorders". Invited lecture for pharmacology course for BCM Physician Assistant students, January 22, 2013.
18. "Neurobiological and Behavioral Correlates of Addiction". Invited lecture for MDACC Bio-Behavioral Research Methods course, February 1, 2013.
19. "Current and Planned Research in the De La Garza Laboratory". Invited presentation for the BCM Department of Psychiatry Quarterly Faculty Meeting, February 27, 2013.
20. "Human Laboratory Research Guiding Medications Development for Addiction". Invited lecture for MDACC Bio-Behavioral Research Methods course, March 8, 2013.
21. "Adolescent Brain Development and Addiction". Invited presentation for the Saturday Morning Science Program as part of the BCM Office of Diversity, March 23, 2013.
22. "Brain Development and Neuropsychiatric Disease Vulnerabilities During Adolescence". Invited lecture for BCM Human Development course for BCM 1st year medical students, March 26, 2013.
23. "Neurobiological Basis of Addiction and Medications Testing". Invited lecture for BCM Summer Medical and

- Research Training (SMART) Program, July 22, 2013.
24. "Promises and Pitfalls of Academic Research". Invited presentation for MDACC Cancer Prevention Research Training Program - Career Conversations, July 23, 2013.
  25. "The Neurobiology of Depression and Suicide". Invited lecture for pharmacology course for BCM Physician Assistant students, January 24, 2014.
  26. "The Neurobiological Basis of Drug Addiction". Invited lecture for MDACC Bio-Behavioral Research Methods course, January 31, 2014.
  27. Course Organizer for BCM Translational Biology and Molecular Medicine (TBMM) Bench to Bedside Series Term 4: *Addiction Neuroscience*, March 14 - May 2, 2014.
  28. "Evaluation of Varenicline Effects on Nicotine in Rats and Humans". Led discussion for TBMM series, March 14, 2014.
  29. "Medications Testing and the FDA Process of Approval". Invited lecture for MDACC Bio-Behavioral Research Methods course, March 21, 2014.
  30. "Developmental Neurobiology". Invited lecture for BCM Human Development course for BCM 1st year medical students, April 1, 2014.
  31. "Career Trajectory of an Addiction Neuroscientist". Invited presentation for MDACC Cancer Prevention Research Training Program - Career Conversations, July 1, 2014.
  32. "Neurobiological Basis of Addiction". Invited lecture for BCM SMART Program, July 21, 2014.
  33. "The Neurobiology of Depression and Antidepressants to Treat the Disorder". Invited lecture for pharmacology course for BCM Physician Assistant students, January 28, 2015.
  34. "Basic and Clinical Science of Addiction". Invited lecture for Neurobiology of Disease section of neuroscience course for 2<sup>nd</sup> year BCM Medical Students and 1<sup>st</sup> year Neuroscience graduate students, April 7, 2015.

#### **Lectures Given and Courses Directed at UCLA (2004-2008)**

1. Course: Seminars in Addiction Psychiatry (2004-2008)  
I created this course to provide a comprehensive and integrated overview of basic neuroscience (including CNS pathways, neuronal targets and signaling molecules, and behavior), neuropharmacology, neuroimmunology, neuroendocrinology, genetics, inpatient and outpatient treatment, as well as social and political issues of drug addiction research and treatment. The course also covered topics of grant writing, manuscript preparation, time management, and career development in drug addiction.
2. Course: Addiction Clinic Journal Watch (2004-2008)  
I designed this course to keep participants current on the most important publications in psychiatry, neuroscience and pharmacology journals. The intent was to cover articles just published ("hot off the press").
3. "One Size Does Not Fit All: Establishing Profiles of Addiction". Invited Grand Rounds lecture for the Department of Psychiatry at UCLA, Los Angeles, CA, October 11, 2005.
4. Course: Translational Neuroscience of Drug Addiction (2007-2008)  
I designed this course as an integral part of the NIH-funded P20 Center for Translational Research on the Clinical Neurobiology of Drug Addiction (for which I served as Co-I and Co-Director). The course covered major topics in drug addiction by emphasizing the use of animal models to understand human addiction, and to disclose how findings derived from human studies can be used to expand the development of animal models.
5. Twice annual lectures for UCLA psychiatry PGY2 and PGY3 trainees (co-teaching with T.F. Newton: 2004-2008)
6. Guest lecturer in the Drugs in Society course for UCLA undergraduate students (Course Director: C. Grella, Ph.D.) (2007-2008)
7. Seminar Series: Dinner with Doctor "X" (2007-2008)

#### **Lectures Given and Courses Directed at AECOM (2000-2004)**

1. "Neuropharmacology of Serotonin Systems" and "Neuropharmacology of Antidepressant Action". Bi-annual lectures given to AECOM graduate students in the Neuropharmacology Course (organized by M. Makman, Ph.D. and Anne Etgen, Ph.D.- Departments of Biochemistry and Molecular Pharmacology).

2. Neurobiology of Drug Abuse” and “Neurobiology and Treatment of Anxiety”. Separate annual lectures given to 2<sup>nd</sup> year medical students of AECOM in the Nervous System and Human Behavior Course (organized by S. Walkley, Ph.D. - Department of Neuroscience).
3. “Impact of Ecstasy on Brain Function”. Lecture given to the students participating in the 2001 Minority Summer Research Opportunity Program, May 31, 2001.
4. “A Neurobiological Basis for Aggression”. Led annual workshop discussion for AECOM 1st year medical students in the Introduction to the Patient Course, 2001-2004.

#### Other Teaching Summary:

- 1985 - 1986 Westwood Junior High School, Richardson Independent School District, Richardson, TX. Full-time Teacher: Earth Science.
- 1986 - 1988 University of North Texas, Department of Biology, Denton, TX. Laboratory Instructor: Botany (Spring 1986, Fall 1986), Animal Physiology (Spring 1987, Fall 1987), Graduate Neurobiology (Spring 1987).
- 1988 - 1991 Deer Park High School, Deer Park Independent School District, Deer Park, TX. Full-time Teacher: Physical Science (1988-1991), Intro. Biology (1989), General Biology (1990-1991). Athletics Coach Soccer (1988-1991), Cross Country (1988-1991), Track (1988-1991).
- 1989 - 1991 San Jacinto College, Department of Biological Sciences, Pasadena, TX. Part-time Instructor: Zoology (Spring 1989, Summer 1990, Fall 1990), Botany (Spring 1990), A&P (Spring 1991).
- 1992 - 1993 University of Texas Medical Branch, Department of Anatomy and Neurosciences, Galveston, TX. Laboratory Instructor: Med Neuroscience (Fall 1992, 1993); Co-Instructor: Grad Neurosci SpTop (Spring 1992, 1993).
- 1996 - 1999 Bentley College, Natural Sciences Department, Waltham, MA. Adjunct Assistant Professor: General Biology (Fall 1996, 1997, 1998, Spring 1998, 1999).
- 1999 - 2000 Sacred Heart University, Department of Biology, Fairfield, CT. Adjunct Assistant Professor: The Human Body (Fall 1999, Spring 2000).
- 1999-2000 Quinnipiac College, Department of Biology, Hamden, CT. Adjunct Assistant Professor. Biology 211 - Anatomy & Physiology.

#### Mentoring Information: (\*co-mentor: T. Newton, M.D.)

##### 1. Junior Faculty

- a. Ari D. Kalechstein, Ph.D., 2008-*present*, BCM, Menninger Department of Psychiatry
- b. Sara Wood, A.P.N, R.N., 2009-2012, MDACC, Department of Psychiatry
- c. Jin H. Yoon, Ph.D., 2009-2013, BCM, Menninger Department of Psychiatry
- d. \*Chris D. Verrico, Ph.D., 2011-*present*, BCM, Menninger Department of Psychiatry
- e. Anis Rashid, M.D., 2009-*present*, MDACC, Department of Psychiatry
- f. \*Colin N. Haile, Ph.D., 2010-*present*, BCM, Menninger Department of Psychiatry
- g. Lee C. Chang, M.D., 2010-*present*, BCM, Department of Anesthesiology
- h. Francesco Versace, Ph.D., 2010-*present*, MDACC, Department of Behavioral Sciences
- i. Reuven Samolski, M.D., 2011-*present*, Universidad Peruana Cayetano Heredia, Lima, PERU
- j. Ramiro Salas, Ph.D., 2011-*present*, BCM, Menninger Department of Psychiatry
- k. Philip Baldwin, Ph.D., 2011-*present*, BCM, Menninger Department of Psychiatry
- l. Brian Mozraffi, M.D., 2013-*present*, BCM, Menninger Department of Psychiatry

##### 2. Clinical and Research Fellows/Postdocs

- a. \*Gilles Fleury, M.D., 2005-2007, UCLA
- b. \*Sarah E. Evans, Ph.D., 2005-2007, UCLA

- c. Christina Wei, R.N., Ph.D., 2010-2011, UTHSC-San Antonio, as part of the Interdisciplinary Research Training Institute on Hispanic Drug Abuse at the University of Houston.
- d. \*Martha Trevino, R.N., Ph.D., 2010-2012, BCM
- e. Yong Cui, Ph.D., 2012-*present*, Primary Mentor, MDACC Cancer Prevention Fellowship Program
- f. Stephanie Hernandez, M.D., March 2013 – *present*, BCM, Menninger Department of Psychiatry
- g. Andres Ojeda, M.D., March 2013 – *present*, BCM, Menninger Department of Psychiatry
- h. Monica Wattana, M.D., June 2013 – *present*, MDACC, Department of Anesthesiology

### 3. Graduate Students

- a. Kevin Fabrizio, 2003-2004, Chair of Dissertation Committee, Department of Neuroscience, AECOM
- b. \*J. Brian Jackson, 2004-2008, Member of Dissertation Committee, Department of Neuroscience, UCLA
- c. \*Christopher Culbertson, 2006-2008, Member of Dissertation Committee, Department of Neuroscience, UCLA
- d. Desev Tziortzis, 2006-2010, Member of Dissertation Committee, Department of Psychology, Pepperdine College
- e. James J. Mahoney, III, 2010-2013, Member of Dissertation Committee, Department of Psychology, University of Houston
- f. \*Alex J. Brewer, 2011-*present*, Chair of Dissertation Committee, Department of Pharmacology, BCM
- g. Elyse M. Cornett, 2011-2012, Member of Dissertation Committee, Department of Pharmacology, Toxicology and Neuroscience, LSU Health Sciences Center – Shreveport
- h. Yue-Ming Chen, 2012-*present*, Member of Dissertation Committee, Division of Biostatistics, University of Texas School of Public Health
- i. Ricky Savjani, 2012-*present*, Member of Dissertation Committee, Department of Neuroscience, BCM.
- j. Edwin Alexander, 2012-*present*, Member of Dissertation Committee, Department of Neuroscience, University of Pennsylvania.
- k. \*Joel Eisenhofer, 2013-*present*, Chair of Dissertation Committee, Department of Neuroscience, BCM

### 4. Graduate Students (lab rotations)

- a. Glenn Fried, August-October 2001, AECOM, Department of Neuroscience
- b. Vicki Boss-Edwards, May 2005-February 2006, UCLA, Department of Psychiatry
- c. Adi Jaffe, January-March 2006, UCLA, Department of Psychiatry
- d. Edwin Alexander, October-December, 2009, BCM, Department of Neuroscience
- e. Liz Ross, January-August 2010, University of Houston, Department of Psychology
- f. Jessica Chu, September-December 2011, BCM, Department of Pharmacology
- g. Jinxuan Chang, March-May 2012, BCM, Department of Biochemistry and Molecular Biology
- h. Joel Eisenhofer, March-May 2013, BCM, Department of Neuroscience
- i. Gillian Bradley, August-November 2013, BCM, Department of Neuroscience
- j. Ian McLaughlin, August-November 2013, BCM, TBBM and Department of Neuroscience
- k. Asante Hatcher, January-March 2013, BCM, Department of Neuroscience
- l. Christina Buckley, June 2013-November 2014, BCM Physician Assistant program
- m. Vena Martinez, October-December 2014 BCM, Department of Pharmacology

### 5. Foreign Medical Graduates Awaiting Residency Training (lab rotations/internships)

- a. Tudor Vlad, M.D., May 2002-January 2004, AECOM
- b. Sridevi Vemulapalli, MBBS, February 2003-January 2004, AECOM
- c. Rajendra Paladugu, MBBS, February 2003-May 2004, AECOM
- d. Sadaf Islam, MBBS, June 2008-April 2009, BCM
- e. Mastan Lokireddy, MBBS, June-November 2009, BCM
- f. Chandra Nerumalla, MBBS, June-November 2009, BCM
- g. Harvinder Singh, MBBS, August-November 2009, BCM
- h. Senthil Lakshmanan, MBBS, September 2009-April 2010, BCM
- i. Sarath Bodepudi, MBBS, September 2009-April 2010, BCM
- j. Waseem Abdallah, MBBS, October 2009-Feb 2010, BCM
- k. Navin Rajj, MBBS, November 2009-January 2010, BCM
- l. Farhat Shaheen, MBBS, April-September 2010, BCM

- m. Sankar Kothapalli, MBBS, May-October 2010, BCM
  - n. Muhammed Ashraf, MBBS, September-December 2010, BCM
  - o. Avinish Bodapatti, MBBS, September-December 2010, BCM
6. Undergraduate students (lab rotations/internships)
- a. Robin Mitchell, May-August 2001, AECOM Summer Undergraduate Research Program
  - b. James Mahoney, May-August 2002, Bridgewater College
  - c. Avi Wittlin, May-August 2002, Yeshiva University
  - d. Alicia McCaskie, May-August 2002, AECOM Summer Undergraduate Research Program
  - e. Alexandra Migdal, May-August 2003, AECOM Summer Undergraduate Research Program
  - f. Cordelia Stearns, June-September 2003, AECOM Summer Undergraduate Research Program
  - g. Robin Mitchell, May-August 2003, AECOM Summer Undergraduate Research Program
  - h. Alex Soltren, September 2003-February 2004, AECOM
  - i. Shaquita Tillman, August 2004-June 2005, UCLA
  - j. Nimisha Gandhi, October 2005-January 2006, UCLA
  - k. Polina Berezovskaya, October 2005-January 2006, UCLA
  - l. Donald Noble, December 2005-October 2007, UCLA
  - m. Eric Wagreich, December 2005-April 2006, UCLA
  - n. Karthik Gunnia, October 2005-August 2006, UCLA
  - o. Caitlin Kenny, January-April 2006, UCLA
  - p. Gary Green, November 2004-June 2006, UCLA
  - q. Chara Civitello, March-June 2006, UCLA
  - r. Matthew Costello, March-July 2006, UCLA
  - s. Phillip Yurovsky, June-October 2006, UCLA
  - t. Ashley Dillon, June-September 2006, UCLA
  - u. Anastasia Kosenko, September 2006-June 2007, UCLA
  - v. Mike Sayers, November 2006-May 2007, UCLA
  - w. Asghar Haider, February-June 2007, UCLA
  - x. Noga Gal, July 2006-June 2007, UCLA
  - y. Marissa Meyer, February-June 2007, UCLA
  - z. Jacqueline Lickness, February-December 2007, UCLA
  - aa. Kailyne Van Stavern, April-December 2007, UCLA
  - bb. Sevan Yeghiazarian, May-August 2007, UCLA
  - cc. Nina Desai, February-December 2007, UCLA
  - dd. Sam Nichols, May-December 2007, UCLA
  - ee. David Trefflich, June-December 2007, UCLA
  - ff. Eanas Aboobakar, June-December 2007, UCLA
  - gg. Melinda Kirshner, July-December 2007, UCLA
  - hh. Sunhye Bai, October-December 2007, UCLA
  - ii. Osa Omoyuri, October-December 2007, UCLA
  - jj. Menaka Nagaswaran, October-December 2007, UCLA
  - kk. Daniel Croft, August 2009-May 2012, Rice University
  - ll. Alex Tran, September 2009-May 2010, Rice University
  - mm. Megha Thakkur, January-May 2010, Rice University
  - nn. Trishna Narula, January-May 2010, Rice University
  - oo. Siya Mehtani, August 2009-May 2010, Rice University
  - pp. Nicholas Arnoudse, December 2009-May 2010, Rice University
  - qq. Danielle Michaud, December 2009-May 2010, Rice University
  - rr. Owen Amadin, June-August 2010, Cornell University
  - ss. TuonhVy Dang, September-October 2010, Rice University
  - tt. Sarah Harrison, September-December 2010, University of Houston
  - uu. Ravi Shah, January-May 2011, Rice University
  - vv. Nupur Kikani, October 2010-May 2011, Rice University

- ww. Anam Azimuddin, October 2010-May 2011, Rice University
- xx. Parker Wray, May 2011-August 2013, University of Texas Austin
- yy. Steve Loar, May-August 2011, University of Texas Austin
- zz. Kim Porter, May 2011-January 2012, University of Houston
- aaa. Ben Shapiro, May 2011-March 2012, University of Saint Thomas
- bbb. Anthony Garcia, June-October 2011, Sam Houston State University
- ccc. Mike Kuney, June-November 2011, Houston Community College
- ddd. Jake Keller, October 2013-March 2014, Rice University

7. High School students (lab rotations/internships)

- a. Abha Gupta, May-August 2001, Bronx High School of Science
- b. Anthony Mohabir, May-August 2002, Bronx High School of Science
- c. Sneha Raju, May 2009-August 2010, William P. Clements High School
- d. Patrick Makey, June-August 2010, Jack Yates High School
- e. Harsh Thakkar, May-August 2011, William P. Clements High School

**University Committee Service – Baylor College of Medicine, MDACC, and MEDVAMC**

- 1. BCM Medical School Admissions Committee (2008-2014)
- 2. BCM Institutional Diversity Council (2008-*present*)
- 3. BCM Institutional Review Board for Human Subjects Research (2008-*present*)
- 4. BCM Department of Psychiatry – Research Committee (2008-*present*)
- 5. MEDVAMC, Traumatic Brain Injury Center of Excellence, Steering Committee (2010-*present*)
- 6. Judge for the Houston Premedical Academy Research Symposium (January 25, 2012). Annual event sponsored by the BCM Office of Diversity and Community Outreach.
- 7. Member, BCM Office of Diversity Subgroup (2012)
- 8. BCM President’s Research Working Group, Strategic Planning, Experimental Therapeutics Subgroup (2011-2013)
- 9. BCM President’s Research Working Group, Strategic Planning, Technology Transfer Subgroup (2011-2013)
- 10. BCM, Dan L. Duncan Cancer Center, Cancer Prevention subgroup (2011-*present*)
- 11. BCM, Alkek Experimental Therapeutics Pilot Awards Review Group, May 2014.

**University Committee Service – UCLA (2004-2008)**

- 1. Member, Integrated Substance Abuse Program (ISAP), Institutional Training Grant Review Committee, 2005-2008.
- 2. Member, ISAP, Research and Proposal Development Committee, 2005-2008.
- 3. Member, ISAP, Human Resources, Finance and Space Committee, 2007-2008.
- 4. Member and Co-founder, Brain Research Institute, Stress in Stimulant Abuse and Addiction Affinity Group, 2004-2008.

**University Committee Service – AECOM (2000-2004)**

- 1. Member, Institutional Animal Care and Use Committee, 2000-2004  
Member, Controlled Substances Subcommittee, 2000-2004
- 2. Member, Faculty Senate, 2002-2004
- 3. Honorary Fellow, Hispanic Center of Excellence, 2003-2004
- 4. Consultant, Campus Outreach & Applicant Pool; Consultant, Evaluations, Mentoring & Counseling, 2003-2004